<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lawrence LK Leung, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Pier Mannuccio Mannucci, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Options for anticoagulation have been expanding steadily over the past few decades, providing a greater number of agents for prevention and management of thromboembolic disease. In addition to heparins and vitamin K antagonists, anticoagulants that directly target the enzymatic activity of thrombin and factor Xa have been developed. Appropriate use of these agents requires knowledge of their individual characteristics, risks, and benefits.</p><p>This topic review discusses practical aspects of the use of direct thrombin inhibitors (oral and parenteral) and oral direct factor Xa inhibitors, along with a brief mention of other anticoagulants in development. Indications and efficacy of these agents in specific clinical settings are presented in separate topic reviews on the relevant conditions. (See <a class="local">'Indications and contraindications'</a> below.)</p><p>Management of bleeding and perioperative management of patients receiving direct thrombin inhibitors or direct factor Xa inhibitors is also discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants"</a> and  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a>.)</p><p>The following topic reviews discuss other anticoagulants in clinical use and under investigation:</p><p class="bulletIndent1"><span class="glyph">●</span>Heparins – (See  <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Vitamin K antagonists – (See  <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects"</a> and  <a class="medical medical_review" href="/z/d/html/1337.html" rel="external">"Biology of warfarin and modulators of INR control"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Fondaparinux – (See  <a class="medical medical_review" href="/z/d/html/1319.html" rel="external">"Fondaparinux: Dosing and adverse effects"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Investigational – (See  <a class="medical medical_review" href="/z/d/html/138700.html" rel="external">"Investigational anticoagulants"</a>.)</p><p></p><p class="headingAnchor" id="H1637554"><span class="h1">MECHANISMS OF ACTION AND TERMINOLOGY</span></p><p class="headingAnchor" id="H1641458"><span class="h2">Sites of action</span><span class="headingEndMark"> — </span>Hemostasis involves several processes. These include platelet activation, generation of fibrin by activated coagulation factors, inhibition of procoagulant factors to prevent excessive clot propagation, and fibrinolysis to dissolve the fibrin clot as the endothelial surface is repaired  (<a class="graphic graphic_figure graphicRef69920" href="/z/d/graphic/69920.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef90873" href="/z/d/graphic/90873.html" rel="external">figure 2</a>).</p><p>Although these processes are often described separately, there are multiple points of overlap and crosstalk between platelets, procoagulant factors, endogenous anticoagulant and fibrinolytic factors, and the endothelium, to promote an appropriate level of hemostasis and limit clot formation to sites of vessel injury. (See  <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">"Overview of hemostasis"</a>.)</p><p>The direct thrombin inhibitors and direct factor Xa inhibitors block major procoagulant activities involved in the generation of a fibrin clot  (<a class="graphic graphic_figure graphicRef94856" href="/z/d/graphic/94856.html" rel="external">figure 3</a>). Each direct inhibitor only blocks one enzyme (direct thrombin inhibitors only block thrombin; direct factor Xa inhibitors only block factor Xa).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thrombin</strong> – Thrombin (factor IIa) is the final enzyme of the clotting cascade that produces fibrin; it is formed by the proteolytic cleavage of prothrombin by factor Xa. Thrombin has a central role in coagulation: it cleaves fibrinogen to fibrin; activates other procoagulant factors including factors V, VIII, XI, and XIII; and activates platelets [<a href="#rid1">1</a>]. The active site of the thrombin enzyme is buried deep in a groove on one side of the molecule  (<a class="graphic graphic_figure graphicRef97057" href="/z/d/graphic/97057.html" rel="external">figure 4</a>); this deep groove and surrounding amino acids enhance the specificity of the enzyme [<a href="#rid2">2,3</a>]. (See  <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Thrombin generation'</a>.)</p><p></p><p class="bulletIndent1">Direct thrombin inhibitors (DTIs) can bind to the active site of the thrombin enzyme (univalent DTIs) or to two sites: the active site and "exosite I," a positively charged region of the thrombin molecule that is physically separated from the active site (divalent DTIs) [<a href="#rid1">1,4</a>]. Exosite I is also the site of interaction ("docking") with many physiologic thrombin substrates, including fibrinogen, factor V, protein C, thrombomodulin (a thrombin receptor on endothelial cells), and thrombin receptors (PAR1 and PAR4) on platelets [<a href="#rid2">2-6</a>].</p><p></p><p class="bulletIndent1">Thrombin is active in both circulating and clot-bound forms. Direct thrombin inhibitors are able to block the action of both forms of thrombin because their site of binding to thrombin is not masked by fibrin (or binding is not obstructed). In contrast, heparins are only able to inactivate thrombin in the fluid phase, via antithrombin (previously called antithrombin III) [<a href="#rid7">7-10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factor Xa</strong> – Factor Xa acts immediately upstream of thrombin in the clotting cascade, at the convergence point of the intrinsic and extrinsic coagulation pathways  (<a class="graphic graphic_figure graphicRef69920" href="/z/d/graphic/69920.html" rel="external">figure 1</a>); it is formed by the proteolytic cleavage of factor X by one of two X-ase (ten-ase) complexes, which are made up of other procoagulant factors. Inhibition of factor Xa can prevent amplified thrombin generation because one molecule of factor Xa can cleave over 1000 molecules of prothrombin to thrombin [<a href="#rid11">11</a>]. Direct factor Xa inhibitors bind to the active site of factor Xa and inhibit factor Xa activity without a requirement for cofactors [<a href="#rid12">12,13</a>]. (See  <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">"Overview of hemostasis", section on 'Multicomponent complexes'</a>.)</p><p></p><p class="bulletIndent1">Similarly to thrombin, factor Xa is active in circulating and clot-bound forms. Direct factor Xa inhibitors are able to block the action of both forms of factor Xa, whereas indirect factor Xa inhibitors such as heparin and <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a> (the antithrombin-binding pentasaccharide) are only able to inactivate factor Xa in the fluid phase, via antithrombin.</p><p></p><p class="headingAnchor" id="H1642544"><span class="h2">Terminology</span><span class="headingEndMark"> — </span>Terminology for anticoagulants continues to evolve as new agents become available. The following terminology describes agents in clinical use:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antithrombotic agent</strong> – Antithrombotic agents include both antiplatelet agents (eg, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>) as well as anticoagulants.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anticoagulant</strong> – Anticoagulants include a variety of agents that inhibit one or more steps in the coagulation cascade. Their mechanisms vary, including direct enzymatic inhibition, indirect inhibition by binding to antithrombin, and antagonism of vitamin K-dependent factors by preventing their synthesis in the liver and/or modification of their calcium-binding properties. Available agents include <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a>, low molecular weight heparins, <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">fondaparinux</a>, vitamin K antagonists, direct thrombin inhibitors, direct factor Xa inhibitors, and other agents at various stages of development. (See  <a class="medical medical_review" href="/z/d/html/138700.html" rel="external">"Investigational anticoagulants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Direct thrombin inhibitor</strong> – Direct thrombin inhibitors (DTIs) prevent thrombin from cleaving fibrinogen to fibrin. They bind to thrombin directly, rather than by enhancing the activity of antithrombin, as is done by heparin.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Parenteral DTIs include <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a> (Angiomax) and <a class="drug drug_general" data-topicid="8765" href="/z/d/drug information/8765.html" rel="external">argatroban</a> (Argatra, Novastan, Arganova, Exembol). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The only oral DTI available for clinical use is <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a> etexilate (Pradaxa).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Direct factor Xa inhibitor</strong> – Direct factor Xa inhibitors prevent factor Xa from cleaving prothrombin to thrombin. They bind directly to factor Xa, rather than enhancing the activity of antithrombin, as is done by heparin.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There are no parenteral direct factor Xa inhibitors in clinical use.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Several oral agents are available, including <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> (Xarelto), <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> (Eliquis), and <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a> (Lixiana, Savaysa). The generic names for these agents all end in "Xa-ban" (eg, rivaro<strong>xaban</strong>, api<strong>xaban</strong>, edo<strong>xaban</strong>).</p><p></p><p>Acronyms that have been created to refer to the orally acting direct thrombin inhibitors and direct factor Xa inhibitors together include direct oral anticoagulants (DOACs), target-specific oral anticoagulants (TSOACs), oral direct inhibitors (ODIs), and NOACs, which stands for "novel oral anticoagulants," "new(er) oral anticoagulants," and "non-vitamin K antagonist oral anticoagulants" [<a href="#rid14">14-17</a>]. The term DOAC is commonly used.</p><p class="headingAnchor" id="H1637547"><span class="h1">COMPARISON WITH HEPARIN AND WARFARIN</span><span class="headingEndMark"> — </span>Anticoagulants differ in efficacy depending on the clinical setting; there are also differences in dosing, monitoring, cost, and risks. Thus, advantages and disadvantages of each agent must be individualized to the patient and clinical setting  (<a class="graphic graphic_table graphicRef91199" href="/z/d/graphic/91199.html" rel="external">table 1</a>). Recommendations for each agent are based largely on the efficacy and safety in the specific patient population and clinical indications.</p><p>However, there are settings in which efficacy and safety of long-term oral administration are similar for vitamin K antagonists and DOACs. In such cases it may be worth considering some additional advantages and disadvantages of each class of drugs in decision making [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H829944185"><span class="h2">Clinician familiarity with dosing</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">Dabigatran</a> was the first of the DOACs to become clinically available (approved in 2010 in the United States). The direct factor Xa inhibitors became available in subsequent years. However, many clinicians remain unfamiliar with the appropriate dosing of these drugs.</p><p>The lack of clinician familiarity with recommended dosing was illustrated in a 2017 report involving over 1500 patients with venous thromboembolism (VTE) who were treated with a DOAC [<a href="#rid19">19</a>]. For initial therapy, use of a dose or dosing frequency that differed from the product labeling was common (rivaroxaban: 287 of 1591 patients [18 percent]; apixaban: 22 of 44 patients [50 percent]). There were similar degrees of deviation from the recommended doses in patients receiving long-term DOAC therapy (rivaroxaban: 14 percent; apixaban: 36 percent; dabigatran: 46 percent). Deviations from recommended dosing typically involved a dose or dosing frequency that was lower than recommended (eg, once-daily dosing instead of twice-daily dosing), and these deviations from recommended dosing correlated with higher rates of VTE recurrence (adjusted hazard ratio [HR] 10.5). Rates of bleeding and death were not different from patients who received the correct dose. In another study in patients with atrial fibrillation, under-dosing of DOACs was associated with inferior outcomes [<a href="#rid20">20</a>].</p><p>It is often stated that clinicians should become familiar with one of the DOACs and use that drug when a DOAC is indicated. However, differences among these drugs, as described below, as well as institutional or pharmacy preferences, may make a different drug a better choice for a given patient. Thus, it is important to develop familiarity with key aspects of prescribing different agents.</p><p class="headingAnchor" id="H1935778240"><span class="h2">Chronic kidney disease</span><span class="headingEndMark"> — </span>All of the DOACs are excreted by the kidney to some degree, which has led to some concern about use and dose adjustments in individuals with chronic kidney disease. A general approach is as follows: </p><p class="bulletIndent1"><span class="glyph">●</span>In hospitalized patients with chronic kidney disease (CKD), heparin is generally used.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For outpatients with mild-to-moderate CKD (CrCl 30 to 50 mL/minute or higher), the evidence discussed above suggests that DOACs are equally effective as <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> and at least as safe, probably safer. Dose adjustments may be appropriate, as discussed below under the specific agents. (See <a class="local">'Dosing (dabigatran)'</a> below and <a class="local">'Dosing, monitoring, risks (rivaroxaban)'</a> below and <a class="local">'Dosing, monitoring, risks (apixaban)'</a> below and <a class="local">'Edoxaban'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For outpatients with severely impaired kidney function (CrCl &lt;30 mL/minute), there is limited evidence to predict how DOACs may compare with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, although evidence for superior efficacy and safety over warfarin continues to accumulate. Warfarin or dose-adjusted low molecular weight (LMW) heparin  (<a class="graphic graphic_table graphicRef90258" href="/z/d/graphic/90258.html" rel="external">table 2</a>) is generally preferred over a DOAC in those with a CrCl &lt;30 mL/minute who require long-term anticoagulation.</p><p></p><p>The approximate degrees of excretion by the kidney are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">Dabigatran</a> – 80 to 85 percent</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">Edoxaban</a> – 35 percent</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">Rivaroxaban</a> – 35 percent</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">Apixaban</a> – 25 percent</p><p></p><p>Despite these concerns, use of DOACs in individuals with CKD appears to be safe and effective, especially in individuals with mild-to-moderate CKD. A 2019 meta-analysis that included 45 trials (34,000 patients, most with atrial fibrillation) reported a statistically significant benefit over <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> in reducing the risk of stroke in those with atrial fibrillation who had mild-to-moderately impaired kidney function (risk ratio [RR] 0.79, 95% CI 0.66-0.93), without an obvious increase in bleeding (RR for major bleeding 0.80, 95% CI 0.61-1.04; RR for intracranial hemorrhage [ICH] 0.49, 95% CI 0.30-0.80) and a trend toward improved survival (RR 0.88, 95% CI 0.78-0.99) [<a href="#rid21">21</a>]. Individuals with end-stage kidney disease (estimated glomerular filtration rate [GFR] &lt;15 mL/minute/1.73 m<sup>2</sup> or creatinine clearance [CrCl] &lt;20 mL/minute) were mostly excluded. A 2020 systematic review that included nine studies (two of which were randomized trials) of individuals with atrial fibrillation or VTE who had CKD or were receiving dialysis found similar efficacy with DOACs versus warfarin and similar bleeding risks with <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> versus warfarin [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H3209078"><span class="h2">Drug adherence</span><span class="headingEndMark"> — </span>Drug adherence appears to be relatively similar in large populations, although these may differ in some individuals or clinical settings. A set of strategies to maximize drug adherence and minimize bleeding have been published [<a href="#rid23">23</a>]. These emphasize useful ways to ask about compliance, reminders about medication storage, counseling about missed doses, planning for surgical procedures, avoidance of prescribed and nonprescription medications that interfere with platelet function (unless medically indicated), monitoring of kidney function, aggressive management of hypertension, and approaches to minimizing the risk of falls.</p><p>The similar adherence to DOACs versus <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> was demonstrated in a meta-analysis of randomized trials (18 trials, 101,801 patients) that evaluated drug discontinuation rates in patients with VTE or atrial fibrillation (AF), who were treated for more than 12 weeks with a DOAC or a pharmacologically active comparator [<a href="#rid24">24</a>]. Individuals receiving a DOAC had similar rates of drug discontinuation to those receiving a vitamin K antagonist, both for VTE (13 versus 14 percent; relative risk [RR] 0.91, 95% CI 0.74-1.13) and for AF (22 percent for both types of agent; RR 1.01, 95% CI 0.87-1.17).</p><p>A review of 4863 patients who were prescribed <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a> for atrial fibrillation found a median adherence rate of 74 percent (interquartile range, 66 to 80 percent) [<a href="#rid25">25</a>]. Adherence was higher at institutions that preselected patients for the ability to adhere to twice-daily medication and at those that provided pharmacist-based patient education and greater communication regarding medication use. Lower adherence rates could be improved by instituting these measures.</p><p>Patients prescribed a DOAC who do not or cannot take the medication as prescribed may have a greater amount of time during which they are not therapeutically anticoagulated compared with patients who miss occasional doses of warfarin. The ability to monitor the degree of nonadherence is lost when a DOAC is substituted for <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>. As noted below, a single missed dose of a DOAC has greater potential to result in inadequate anticoagulation than a single missed dose of warfarin. (See <a class="local">'Settings in which a heparin or vitamin K antagonist may be preferable'</a> below.)</p><p class="headingAnchor" id="H1641052"><span class="h2">Advantages over heparin and warfarin</span><span class="headingEndMark"> — </span>The DOACs differ significantly from vitamin K antagonists in their onset of action, half-life, drug-drug interactions, need for monitoring, ability to monitor should this be called into question, as well as availability of antidotes in the case of excessive bleeding  (<a class="graphic graphic_table graphicRef91199" href="/z/d/graphic/91199.html" rel="external">table 1</a>). In some cases, these differences may translate into similar efficacy with greater ease of administration and lower bleeding risk. However, as noted above, the efficacy and bleeding risk depend on patient variables such as compliance and interacting medications, and all decisions must be individualized to take these factors into account.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lower bleeding risk</strong> – Overall, all-cause mortality from DOACs appears to be lower than that from <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, driven primarily by a decrease in fatal intracranial bleeding risks [<a href="#rid26">26</a>]. However, direct comparison of bleeding risk with different agents is challenging because risks appear to vary in different patient populations and clinical settings, and meta-analysis often combines different doses of the same anticoagulant [<a href="#rid27">27</a>]. This issue is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/119889.html" rel="external">"Risks and prevention of bleeding with oral anticoagulants", section on 'Risk factors related to the anticoagulant'</a>.)</p><p></p><p class="bulletIndent1">The lower risk of bleeding with DOACs is especially relevant for older adults. A 2023 update of the American Geriatric Society (AGS) Beers criteria advises avoidance of <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> and use of a DOAC for VTE or nonvalvular AF unless there are substantial barriers or contraindications to using a DOAC [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Possible lower risk of fractures</strong> – The risk of fractures has not been evaluated in a randomized trial, but a series of observational studies suggest that DOACs are associated with lower risk of fractures than warfarin. One retrospective series of nearly 170,000 individuals with atrial fibrillation who were started on a new anticoagulant found a lower fracture risk of the ensuing 13 months with DOACs over <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> (hazard ratio [HR] 0.78, 95% CI 0.79-0.96) [<a href="#rid29">29</a>]. The finding was most impressive for people with preexisting osteoporosis and with <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> versus warfarin. A second retrospective series of nearly 20,000 individuals followed for 2.4 years reported remarkably similar findings supporting a lower risk with DOACs (HR 0.84, 95% CI 0.77-0.93) with the greatest decrease seen with apixaban [<a href="#rid30">30</a>]. An earlier study observed a lower risk of fractures with dabigatran compared with warfarin [<a href="#rid31">31-33</a>].</p><p></p><p class="bulletIndent1">The reason for this difference in fracture risk, if real, is unknown. Nor is it clear whether it represents an increase over baseline risk with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> or a decrease from baseline risk with DOACs. Suggested mechanisms range from a difference in risk of falls to alterations in bone biology. (See  <a class="medical medical_review" href="/z/d/html/2044.html" rel="external">"Pathogenesis of osteoporosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Less laboratory monitoring</strong> – Heparin and warfarin both have a relatively narrow therapeutic window and more variable dose-response relationship that depends on a variety of factors; these features lead to a requirement for frequent monitoring of clotting times to optimize the therapeutic dose range and prevent bleeding [<a href="#rid34">34,35</a>]. Dose may be affected by differing bioavailability, diet, and acute medical illnesses. In contrast, the DOACs are generally used without a requirement for monitoring of drug levels or coagulation (clotting) times. This is an advantage for patients for whom frequent monitoring is a greater burden. It remains to be determined whether laboratory monitoring of any of the DOACs can further improve their efficacy or safety. (See <a class="local">'Laboratory testing and monitoring (dabigatran)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preferable pharmacokinetics</strong> – Warfarin pharmacokinetics is affected by the level of vitamin K intake and production in the gastrointestinal tract, as well as induction of hepatic cytochromes. Thus, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> effect can be altered by changes in diet, administration of other medications, gastrointestinal disorders, and reduced oral intake. Patients with difficulty controlling the prothrombin time/international normalized ratio (PT/INR) may benefit from a DOAC because these agents have less variability in drug effect for a given dose than vitamin K antagonists. Affected patients may include those with unavoidable drug-drug interactions (such as frequent need for antibiotics or a large number of concomitant and variable medications) or unexplained poor warfarin control. However, it is important to determine that the INR instability with a vitamin K antagonist is not due to poor compliance, which may be easier to monitor for vitamin K antagonists than for the target-specific agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Favorable biology </strong>– The biology of the parenteral direct thrombin inhibitors (bivalirudin, argatroban) may give them advantages over heparins in certain clinical settings such as percutaneous cardiac interventions, where inhibition of clot-bound thrombin might be important; and heparin-induced thrombocytopenia (HIT), where induction of an aggressive hypercoagulable state (due to anti-heparin-PF4 antibodies) must be avoided. (See <a class="local">'Indications and contraindications'</a> below.) </p><p></p><p class="headingAnchor" id="H1641059"><span class="h2">Settings in which a heparin or vitamin K antagonist may be preferable</span><span class="headingEndMark"> — </span>There are several settings in which warfarin may be preferable to one of the DOACs, or in which a DOAC is contraindicated (eg, mechanical prosthetic heart valve, pregnancy)  (<a class="graphic graphic_table graphicRef91199" href="/z/d/graphic/91199.html" rel="external">table 1</a>). In addition, patients who are receiving <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> with excellent stable INR control and minimal bleeding side effects may have little to gain by switching to a different agent. In many inpatient settings, heparins are preferable because of similar efficacy to parenteral direct thrombin inhibitors, availability of an antidote, and substantially lower costs.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanical prosthetic heart valves</strong> – The direct thrombin inhibitors and direct factor Xa inhibitors are <strong>not</strong> used in patients with mechanical prosthetic heart valves, due to greater risk of valve thrombosis, which may be fatal. (See  <a class="medical medical_review" href="/z/d/html/8171.html" rel="external">"Antithrombotic therapy for mechanical heart valves", section on 'Long-term anticoagulation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pregnancy</strong> – Direct thrombin inhibitors and direct factor Xa inhibitors are <strong>not</strong> used during pregnancy, due to lack of clinical experience in this setting; LMW heparin is preferred in most pregnant women who require an anticoagulant. If a patient taking one of these agents becomes pregnant, she should be switched to LMW heparin immediately. This issue is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic kidney disease</strong> – DOACs are metabolized mostly in the kidney, with apixaban least dependent on clearance by the kidney (approximately 25 percent). Creatinine clearance (CrCl) can be estimated from the patient's sex, age, weight, and serum creatinine (<a class="calc calc_professional" href="/z/d/html/13496.html" rel="external">calculator 1</a> and <a class="calc calc_professional" href="/z/d/html/16104.html" rel="external">calculator 2</a>). Concerns have existed with the use of DOACs in individuals with CrCl less than 30 mL/minute. However, data continue to accumulate, especially in individuals with atrial fibrillation, suggesting that DOACs, especially <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a>, have better to equal efficacy and safety, similar to effects in individuals with normal CrCl. (See <a class="local">'Chronic kidney disease'</a> above and  <a class="medical medical_review" href="/z/d/html/128998.html" rel="external">"Atrial fibrillation in adults: Selection of candidates for anticoagulation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe liver disease</strong> – DOACs are hepatically metabolized to varying degrees, and most clinicians do not use DOACs in individuals with severe hepatic impairment, as shown in the table  (<a class="graphic graphic_table graphicRef117823" href="/z/d/graphic/117823.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiphospholipid syndrome</strong> – In patients with the antiphospholipid syndrome (APS) who require anticoagulation, heparin followed by warfarin is the preferred therapy, especially for those with a history of arterial thrombosis or other high-risk features. (See  <a class="medical medical_review" href="/z/d/html/4682.html" rel="external">"Management of antiphospholipid syndrome", section on 'Long-term anticoagulation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adherence</strong> – Use of DOACs may be challenging in patients who are unable to take their medication as prescribed. The lack of routine monitoring and short half-lives of these agents make it more difficult to determine if a patient is taking them appropriately. In addition, missing one or two doses can leave the patient inadequately anticoagulated; in contrast, missing a couple of doses of <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> is unlikely to substantially increase the time outside the therapeutic range.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal disease</strong> – Patients with gastrointestinal diseases, especially those with a history of bleeding, may prefer to avoid the direct factor Xa inhibitors because of an increased bleeding risk. Individuals with severe dyspepsia may not tolerate <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a>. (See <a class="local">'Risks (dabigatran)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Altered gastrointestinal anatomy</strong> – Individuals who have undergone gastrectomy or weight reduction surgeries such as gastric bypass may have altered absorption of the DOACs. Some experts consider this a reason to avoid DOAC and would use a different anticoagulant such as heparin or <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, for which therapeutic drug monitoring is available. Another alternative if a DOAC is used is to measure drug levels to confirm absorption. (See <a class="local">'High BMI and post-bariatric surgery'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing convenience</strong> – Dabigatran and apixaban are taken twice daily, which may cause an increased burden for patients who place a higher value on taking a single daily dose of an anticoagulant. European labeling for dabigatran includes once daily dosing. Rivaroxaban and edoxaban have a once daily dosing schedule, as does warfarin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cost</strong> – Vitamin K antagonists are typically much less expensive than DOACs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inability to titrate the dose</strong> – Individuals with an aggressive hypercoagulable state may have recurrent thrombosis despite adequate anticoagulation. For individuals with warfarin, one approach is to target a higher INR. This type of dose titration is not validated for DOACs. </p><p></p><p class="headingAnchor" id="H1640976"><span class="h1">INDICATIONS AND CONTRAINDICATIONS</span><span class="headingEndMark"> — </span>Clinical indications for direct thrombin inhibitors and direct factor Xa inhibitors in various settings are discussed in separate topic reviews:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Venous thromboembolism (VTE) prophylaxis (non-orthopedic)</strong> – (See  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>VTE prophylaxis (orthopedic)</strong> – (See  <a class="medical medical_review" href="/z/d/html/1335.html" rel="external">"Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>VTE treatment (individuals without cancer, initial anticoagulation)</strong> – (See  <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">"Venous thromboembolism: Initiation of anticoagulation", section on 'Direct factor Xa and thrombin inhibitors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>VTE treatment (individuals without cancer, long-term anticoagulation)</strong> – (See  <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">"Venous thromboembolism: Anticoagulation after initial management", section on 'Direct thrombin and factor Xa inhibitors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>VTE treatment (individuals with cancer)</strong> – (See  <a class="medical medical_review" href="/z/d/html/1340.html" rel="external">"Anticoagulation therapy for venous thromboembolism (lower extremity venous thrombosis and pulmonary embolism) in adult patients with malignancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atrial fibrillation (AF)</strong> – (See  <a class="medical medical_review" href="/z/d/html/128998.html" rel="external">"Atrial fibrillation in adults: Selection of candidates for anticoagulation"</a> and  <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute coronary syndromes (ACS)</strong> – (See  <a class="medical medical_review" href="/z/d/html/93.html" rel="external">"Anticoagulant therapy in non-ST elevation acute coronary syndromes"</a> and  <a class="medical medical_review" href="/z/d/html/92.html" rel="external">"Acute ST-elevation myocardial infarction: Management of anticoagulation"</a> and  <a class="medical medical_review" href="/z/d/html/1577.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: Clinical studies", section on 'Bivalirudin'</a> and  <a class="medical medical_review" href="/z/d/html/101.html" rel="external">"Acute coronary syndrome: Oral anticoagulation in medically treated patients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heparin-induced thrombocytopenia (HIT)</strong> – (See  <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">"Management of heparin-induced thrombocytopenia", section on 'Direct oral anticoagulants'</a> and  <a class="medical medical_review" href="/z/d/html/118004.html" rel="external">"Management of heparin-induced thrombocytopenia (HIT) during cardiac or vascular surgery"</a>.)</p><p></p><p>These agents are <strong>not </strong>used in individuals with mechanical prosthetic heart valves, severe kidney disease, pregnancy, or antiphospholipid syndrome (APS). (See  <a class="medical medical_review" href="/z/d/html/8171.html" rel="external">"Antithrombotic therapy for mechanical heart valves"</a> and  <a class="medical medical_review" href="/z/d/html/4682.html" rel="external">"Management of antiphospholipid syndrome"</a>.)</p><p>Possible contraindications to anticoagulation are listed in the table  (<a class="graphic graphic_table graphicRef107527" href="/z/d/graphic/107527.html" rel="external">table 4</a>); however, this list is not intended to substitute for the judgment of the treating clinician who is able to weigh the risks and benefits for the individual patient.</p><p class="headingAnchor" id="H319857486"><span class="h1">BLEEDING</span></p><p class="headingAnchor" id="H1174916075"><span class="h2">Risks of bleeding and prevention strategies</span><span class="headingEndMark"> — </span>The risk of bleeding with DOACs is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/119889.html" rel="external">"Risks and prevention of bleeding with oral anticoagulants"</a>.)</p><p class="headingAnchor" id="H2433090644"><span class="h2">Management of bleeding</span><span class="headingEndMark"> — </span>Separate topic reviews discuss the management of bleeding and perioperative management in individuals receiving DOACs:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antidotes</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dabigatran</strong> – (See  <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants", section on 'Dabigatran reversal'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Factor Xa inhibitors</strong> – (See  <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants", section on 'Factor Xa inhibitors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other aspects of bleeding management</strong> – (See  <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants", section on 'Major bleeding'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of invasive procedure/surgery</strong> – (See  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a>.)</p><p></p><p class="headingAnchor" id="H7"><span class="h1">DIRECT THROMBIN INHIBITORS</span><span class="headingEndMark"> — </span>Direct thrombin inhibitors inactivate circulating and clot-bound thrombin (factor IIa)  (<a class="graphic graphic_figure graphicRef94856" href="/z/d/graphic/94856.html" rel="external">figure 3</a>). This may be especially important in individuals with coronary thrombosis. (See  <a class="medical medical_review" href="/z/d/html/93.html" rel="external">"Anticoagulant therapy in non-ST elevation acute coronary syndromes", section on 'Unfractionated heparin compared with bivalirudin'</a>.)</p><p>Unlike heparin, the direct thrombin inhibitors do not bind to platelet factor 4 (PF4) and thus are not able to induce or react with the anti-heparin/PF4 antibodies that cause heparin-induced thrombocytopenia (HIT). Thus, the parenteral direct thrombin inhibitors are options for anticoagulation in patients with HIT. (See  <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">"Management of heparin-induced thrombocytopenia", section on 'Anticoagulation'</a>.)</p><p class="headingAnchor" id="H1642807"><span class="h2">Parenteral direct thrombin inhibitors</span><span class="headingEndMark"> — </span>Parenteral direct thrombin inhibitors include <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a> and <a class="drug drug_general" data-topicid="8765" href="/z/d/drug information/8765.html" rel="external">argatroban</a>. These agents directly block the actions of thrombin  (<a class="graphic graphic_figure graphicRef94856" href="/z/d/graphic/94856.html" rel="external">figure 3</a>). (See <a class="local">'Bivalirudin'</a> below and <a class="local">'Argatroban'</a> below.)</p><p class="headingAnchor" id="H11"><span class="h3">Bivalirudin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">Bivalirudin</a> (Angiomax, previously called Hirulog) is a synthetic 20 amino acid peptide that binds to the thrombin catalytic site and exosite I, reversibly inhibiting thrombin enzymatic activity [<a href="#rid36">36</a>]. The peptide sequence is an analog of hirudin, a protein extracted from the salivary gland of the medicinal leech. (See <a class="local">'Sites of action'</a> above.)</p><p>The indications and use of <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a> in patients undergoing percutaneous coronary interventions (PCI) and heparin induced thrombocytopenia (HIT) are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>PCI – (See  <a class="medical medical_review" href="/z/d/html/1577.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: Clinical studies", section on 'Bivalirudin'</a> and  <a class="medical medical_review" href="/z/d/html/93.html" rel="external">"Anticoagulant therapy in non-ST elevation acute coronary syndromes"</a> and  <a class="medical medical_review" href="/z/d/html/92.html" rel="external">"Acute ST-elevation myocardial infarction: Management of anticoagulation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HIT – (See  <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">"Management of heparin-induced thrombocytopenia"</a>.)</p><p></p><p><a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">Bivalirudin</a> is administered at a dose of 0.75 mg/kg intravenously as a bolus followed by 1.75 mg/kg per hour during a procedure. Patients with kidney failure do not require a change in the bolus dose; those with creatinine clearance (CrCl) &lt;30 mL/minute may use a lower infusion rate (eg, 1 mg/kg per hour) [<a href="#rid36">36</a>]. Intravenous administration produces an immediate anticoagulant effect. The half-life of bivalirudin is approximately 25 minutes; prolonged coagulation times return to normal approximately one hour after discontinuation [<a href="#rid37">37</a>]. The drug is metabolized in kidney, liver, and other sites [<a href="#rid1">1</a>]. Bivalirudin can be hemodialyzed.</p><p><a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">Bivalirudin</a> can be monitored by the activated clotting time (ACT); it acts rapidly, and the effect can be tested within minutes of administration. Monitoring can also be performed using the activated partial thromboplastin time (aPTT), with a target of 1.5 to 2.5 times the normal range. Patients with impaired kidney function should be monitored with an activated clotting time; the therapeutic range varies with the device used.</p><p class="headingAnchor" id="H16278932"><span class="h3">Argatroban</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8765" href="/z/d/drug information/8765.html" rel="external">Argatroban</a> (Arganova, Argaron, Argatra, Da Bei, Exembol, Gartban, Novastan, Slonon) is a synthetic peptide-based direct thrombin inhibitor that interacts with the active site of thrombin [<a href="#rid38">38</a>]. It has a short in vivo plasma half-life (terminal elimination half-life approximately 40 to 50 minutes) [<a href="#rid39">39</a>]. (See <a class="local">'Sites of action'</a> above.)</p><p>Dosing and monitoring of <a class="drug drug_general" data-topicid="8765" href="/z/d/drug information/8765.html" rel="external">argatroban</a> differs depending on the indication:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Heparin-induced thrombocytopenia (HIT)</strong> – For patients with HIT who have normal hepatic function, <a class="drug drug_general" data-topicid="8765" href="/z/d/drug information/8765.html" rel="external">argatroban</a> is administered at an initial dose of 2 mcg/kg per minute intravenously as a continuous infusion [<a href="#rid39">39</a>]. Monitoring is done by the aPTT; a baseline aPTT should be obtained prior to administration, and the aPTT should be repeated two hours after starting therapy, and after any dose changes. The dose is adjusted to achieve a target aPTT of 1.5 to 3 times the initial baseline value, not to exceed 100 seconds [<a href="#rid39">39</a>]. Further details of the use of argatroban in HIT are presented separately. (See  <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">"Management of heparin-induced thrombocytopenia", section on 'Argatroban'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Percutaneous coronary intervention (PCI)</strong> – For PCI in patients with HIT or at high risk for HIT, <a class="drug drug_general" data-topicid="8765" href="/z/d/drug information/8765.html" rel="external">argatroban</a> is given as a bolus of 350 mcg/kg over three to five minutes, with an infusion of 25 mcg/kg per minute. Monitoring is done by the activated clotting time. Parameters are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1576.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: General use", section on 'Heparin-induced thrombocytopenia'</a>.)</p><p></p><p>Argatroban is hepatically metabolized, and dosing adjustment is advised in patients with hepatic impairment [<a href="#rid1">1</a>]. Dose adjustment is not required in patients with impaired kidney function [<a href="#rid39">39,40</a>].</p><p><a class="drug drug_general" data-topicid="8765" href="/z/d/drug information/8765.html" rel="external">Argatroban</a> prolongs the prothrombin time/international normalized ratio (PT/INR). When patients receiving argatroban are transitioned to <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, an adjusted INR target must be used during the overlap, and the INR must be repeated after discontinuation of argatroban. Institutional guidelines regarding the appropriate INR target should be followed.</p><p class="headingAnchor" id="H12"><span class="h2">Oral direct thrombin inhibitor</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">Dabigatran</a> is the only oral direct thrombin inhibitor available for clinical use. Additional agents are under development (eg, AZD-0837) [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H14"><span class="h3">Dabigatran</span></p><p class="headingAnchor" id="H89170812"><span class="h4">Overview (dabigatran)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">Dabigatran</a> etexilate (Pradaxa) is an orally administered prodrug that is converted in the liver to dabigatran, an active direct thrombin inhibitor that inhibits clot-bound and circulating thrombin [<a href="#rid42">42</a>]. The half-life is approximately 12 to 17 hours in individuals with normal kidney function. Absorption is unaffected by food.</p><p>Importantly, dabigatran capsules should only be dispensed and stored in the original bottle (with desiccant) or blister package in which they came, due to the potential for product breakdown from moisture and resulting loss of potency. Patients should not store or place this agent in any other container, such as pill boxes or pill organizers. Once the bottle is opened, the pills inside must be used within four months [<a href="#rid43">43</a>]. The capsules should not be crushed or opened before administration, as removal of the capsule shell results in dramatic increases in oral bioavailability [<a href="#rid44">44</a>].</p><p><a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">Dabigatran</a> is used in the prevention and management of VTE disease, in stroke prevention in patients with atrial fibrillation (AF), and in ischemic heart disease. These indications are discussed in detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>VTE prophylaxis – (See  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>VTE overview of treatment – (See  <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>VTE initial treatment – (See  <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">"Venous thromboembolism: Initiation of anticoagulation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>VTE extended treatment – (See  <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">"Venous thromboembolism: Anticoagulation after initial management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>AF – (See  <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Ischemic heart disease – (See  <a class="medical medical_review" href="/z/d/html/69.html" rel="external">"Perioperative myocardial infarction or injury after noncardiac surgery"</a> and  <a class="medical medical_review" href="/z/d/html/1535.html" rel="external">"Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy"</a>.)</p><p></p><p>Dabigatran should not be used in patients with mechanical prosthetic heart valves or during pregnancy. (See  <a class="medical medical_review" href="/z/d/html/8171.html" rel="external">"Antithrombotic therapy for mechanical heart valves"</a> and  <a class="medical medical_review" href="/z/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum"</a>.)</p><p class="headingAnchor" id="H10489655"><span class="h4">Dosing (dabigatran)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">Dabigatran</a> is generally given at a fixed dose without monitoring  (<a class="graphic graphic_table graphicRef112514" href="/z/d/graphic/112514.html" rel="external">table 5</a>). It is important to use the appropriate dose (ie, do not under-dose). Maximum anticoagulant effects are achieved within two to three hours of ingestion [<a href="#rid45">45</a>]. Excretion of unchanged drug by the kidney is the predominant elimination pathway, with approximately 80 percent of an intravenous dose being excreted unchanged in the urine [<a href="#rid46">46,47</a>]. The dosing differs according to the clinical indication and the patient's kidney function [<a href="#rid44">44</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Venous thromboembolism (VTE) primary prophylaxis in surgical patients: 110 mg one to four hours after surgery, followed by 220 mg once daily for 28 to 35 days (hip replacement) or 10 days (knee replacement).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment and secondary prevention of VTE: 150 mg orally twice daily after 5 to 10 days of parenteral anticoagulation (CrCl &gt;30 mL/minute). Adequate treatment for VTE is full-dose anticoagulation for three to six months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stroke prevention in atrial fibrillation (AF): 110 mg orally twice daily or 150 mg orally twice daily (CrCl &gt;30 mL/minute). European labeling suggests dose reduction in patients older than 75 years (eg, 150 mg orally once per day or 110 mg orally twice per day) [<a href="#rid27">27,48</a>]. This is discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants", section on 'Dosing'</a>.)</p><p></p><p>Clinical settings in which dose modification or drug avoidance may be indicated include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic kidney disease</strong> – Dabigatran is excreted by the kidney, and the half-life is extended in patients with impaired kidney function. As an example, a study in volunteers with mild, moderate, and severe chronic kidney disease and kidney failure receiving dialysis found half-lives of approximately 14, 17, 19, 28, and 34 hours, respectively [<a href="#rid46">46</a>]. Dose reduction has been recommended for those with a CrCl in the range of 15 to 30 mL/minute, since such patients otherwise have had marked increases in bleeding events when taking full doses [<a href="#rid49">49</a>]. We reduce the dose in patients with CrCl 15 to 30 mL/minute (eg, 75 mg orally twice daily instead of doses listed above). Product labeling in the United States recommends avoidance of dabigatran in individuals with CrCl &lt;15 mL/minute or in those who are hemodialysis dependent; the Canadian, United Kingdom, and European Medicines Agency labeling recommend avoidance in patients with a CrCl &lt;30 mL/minute [<a href="#rid50">50-52</a>]  (<a class="graphic graphic_table graphicRef112756" href="/z/d/graphic/112756.html" rel="external">table 6</a>). CrCl can be estimated from the patient's sex, age, weight, and serum creatinine (<a class="calc calc_professional" href="/z/d/html/13496.html" rel="external">calculator 1</a> and <a class="calc calc_professional" href="/z/d/html/16104.html" rel="external">calculator 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>P-glycoprotein inhibitors or inducers</strong> – Dabigatran is a substrate for P-glycoprotein. Concomitant use of dabigatran with P-glycoprotein inducers (eg, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>) reduces the anticoagulant effect of dabigatran and generally should be avoided. Concomitant use of dabigatran with P-glycoprotein inhibitors (eg, <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">ketoconazole</a>, <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a>) in patients with kidney failure may increase the anticoagulant effect of dabigatran  (<a class="graphic graphic_table graphicRef112756" href="/z/d/graphic/112756.html" rel="external">table 6</a> and <a class="graphic graphic_table graphicRef73326" href="/z/d/graphic/73326.html" rel="external">table 7</a>) [<a href="#rid44">44</a>]. Official prescribing information and/or a drug interactions resource should be consulted for any questions.</p><p></p><p class="bulletIndent1">By contrast, dabigatran is not metabolized by the cytochrome p450 system (CYP); dose changes are not generally required with concomitant administration of CYP inducers or inhibitors.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>BMI</strong> – Data are limited on the efficacy and safety of dabigatran in individuals with a high body mass index (BMI). Based on a 2021 review of available literature, the International Society on Thrombosis and Haemostasis (ISTH) recommended that any DOAC is appropriate for individuals with BMI up to 40 kg/m<sup>2</sup> or weight up to 120 kg [<a href="#rid53">53</a>]. They recommend use of dabigatran (and other DOACs) at standard dose for patients with a BMI ≤40 kg/m<sup>2</sup> or weight &lt;120 kg. This reflects our general practice, although it should not replace clinical judgment regarding avoidance in individuals with a lower BMI or use in those with a higher BMI.</p><p></p><p>Support for the approach of tailoring dosage according to patient variables such as age or kidney function comes from a study of 100 patients with atrial fibrillation, which found that a lower dose of dabigatran (110 mg twice daily) in patients who were older, of lower body weight, or had lower CrCl, resulted in trough levels that were comparable to the higher dose (150 mg twice daily) in patients who lacked these characteristics [<a href="#rid54">54</a>]. We do not alter dosing for individuals with different ethnic backgrounds.</p><p class="headingAnchor" id="H89174283"><span class="h4">Laboratory testing and monitoring (dabigatran)</span><span class="headingEndMark"> — </span>Laboratory testing prior to initiating <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a> should include platelet count, prothrombin time (PT), and activated partial thromboplastin time (aPTT), to assess and document coagulation status before anticoagulation; and measurement of serum creatinine, as a baseline and for potential dose adjustment in the event of chronic kidney disease.</p><p>Routine laboratory monitoring of coagulation times is not required for patients taking dabigatran, because drug levels are relatively predictable for a given dose, and a therapeutic range has not been established. However, possible improvements in efficacy and/or safety with monitoring of dabigatran drug levels have been suggested, and monitoring recommendations may change [<a href="#rid55">55-60</a>].</p><p>If there is a concern that dabigatran drug levels are abnormally low or abnormally high, it may be appropriate to test for the presence of the drug. A consensus document from the International Council for Standardization in Haematology (ICSH) has provided examples of dabigatran drug levels for the 150 mg twice-daily dose, with an expected mean peak of approximately 157 ng/mL (25<sup>th</sup> to 75<sup>th</sup> percentile of 117 to 275 ng/mL) and an expected trough of approximately 60 to 91 ng/mL (25<sup>th</sup> to 75<sup>th</sup> percentile, 39 to 143 ng/mL) [<a href="#rid61">61</a>]. These values are intended to be used as guides to provide evidence of drug absorption, not as therapeutic targets.</p><p>Settings in which coagulation testing for dabigatran effect may be helpful include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Bleeding in a patient receiving dabigatran, or with suspected dabigatran overdose – (See  <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants", section on 'Assessment of anticoagulation status'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Need for emergency or urgent surgery in a patient receiving dabigatran – (See  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants", section on 'Dabigatran'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concerns about absorption (eg, altered gastrointestinal anatomy) or drug adherence.</p><p></p><p>In such cases, the ecarin clotting time is the best method to assess bleeding risk, but this test is not widely available. Other coagulation tests that are prolonged in the presence of therapeutic doses of dabigatran include the dilute thrombin time (dilute TT), activated partial thromboplastin time (aPTT), and the activated clotting time (ACT). In contrast, the prothrombin time (PT) cannot be used as a reliable measure of dabigatran activity. A study that compared the PT, aPTT, and TT in plasma to which dabigatran had been added found that the TT was the most sensitive test for detecting low levels of dabigatran [<a href="#rid62">62</a>]. There was test-kit variability for all of these assays, emphasizing the need for caution when comparing tests from different studies and/or manufacturers. Some clinicians find the TT too sensitive and prefer to use the aPTT to assess the presence of dabigatran. Point-of-care devices for measuring the PT/international normalized ratio (PT/INR) should not be used [<a href="#rid63">63</a>]. (See  <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">"Clinical use of coagulation tests"</a>.)</p><p class="headingAnchor" id="H27804459"><span class="h4">Risks (dabigatran)</span><span class="headingEndMark"> — </span>As with all anticoagulants, dabigatran increases bleeding risk. An antidote is available (see  <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants", section on 'Dabigatran reversal'</a>). Product labeling for dabigatran has a Boxed Warning regarding the risk of spinal/epidural hematoma in patients undergoing neuraxial anesthesia or spinal puncture [<a href="#rid64">64</a>].</p><p>Bleeding risks of dabigatran compared with other oral anticoagulants have been evaluated in several meta-analyses and large observational series. In general, these have shown that overall bleeding rates are similar with dabigatran compared with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>. Dabigatran may be associated with a slightly lower rate of intracranial hemorrhage and death, and a slightly higher risk of gastrointestinal bleeding at the 150 mg twice daily dose (but not 110 mg twice daily) [<a href="#rid27">27,65-68</a>]. A discussion of bleeding risks and comparison with other oral anticoagulants, including vitamin K antagonists, is presented separately. (See  <a class="medical medical_review" href="/z/d/html/119889.html" rel="external">"Risks and prevention of bleeding with oral anticoagulants"</a>.)</p><p>The management of bleeding and perioperative management in patients receiving dabigatran is also discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants"</a> and  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a>.)</p><p>As with all anticoagulants, dabigatran is administered to individuals with increased thromboembolic risk. Dabigatran has a Boxed Warning regarding the risk of thrombotic events following premature discontinuation [<a href="#rid64">64</a>].</p><p>Dyspepsia is a common side effect of dabigatran, with an incidence from 12 to 33 percent in some studies [<a href="#rid69">69-71</a>]. In the RE-LY trial, which randomly assigned 18,113 individuals with AF to dabigatran or warfarin, non-bleeding gastrointestinal events (dyspepsia, dysmotility, gastrointestinal reflux) were nearly twice as common in those who received dabigatran (16.9 versus 9.4 percent; relative risk [RR] 1.81, 95% CI 1.66-1.97 percent) [<a href="#rid72">72</a>]. This may limit dabigatran use in some patients. (See  <a class="medical medical_review" href="/z/d/html/20.html" rel="external">"Approach to the adult with dyspepsia"</a>.)</p><p>There does not appear to be an increased risk of serious liver injury with dabigatran, despite concerns with an earlier direct thrombin inhibitor that was not approved (ximelagatran). In a cohort study involving 51,887 patients receiving a DOAC (3778 of whom [7 percent] had prior liver disease), the adjusted hazard ratio (HR) for serious liver injury was 0.99 (95% CI 0.68-1.45), and there was a trend towards a lower risk of serious liver injury in the individuals with prior liver injury that did not reach statistical significance (adjusted HR 0.68, 95% CI 0.33-1.37) [<a href="#rid73">73</a>].</p><p class="headingAnchor" id="H15"><span class="h1">DIRECT FACTOR Xa INHIBITORS</span></p><p class="headingAnchor" id="H1146013200"><span class="h2">General considerations for direct factor Xa inhibitors</span><span class="headingEndMark"> — </span>Direct factor Xa inhibitors inactivate circulating and clot-bound factor Xa  (<a class="graphic graphic_figure graphicRef94856" href="/z/d/graphic/94856.html" rel="external">figure 3</a>). Several orally acting direct factor Xa inhibitors are clinically available. (See <a class="local">'Rivaroxaban'</a> below and <a class="local">'Apixaban'</a> below and <a class="local">'Edoxaban'</a> below.)</p><p>There are no parenteral direct factor Xa inhibitors available for clinical use. Otamixaban was developed as an intravenous factor Xa inhibitor, but development was discontinued due to an increased risk of bleeding compared with unfractionated heparin in patients with acute coronary syndromes [<a href="#rid74">74,75</a>].</p><p class="headingAnchor" id="H2380119268"><span class="h3">Differences between factor Xa inhibitors</span><span class="headingEndMark"> — </span>The following differences may warrant consideration in decision-making:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – All of the direct factor Xa inhibitors are effective anticoagulants. However, the twice daily dosing of <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> may result in smaller fluctuations in drug levels over the course of the day. In a retrospective review of more than 37,000 adults with venous thromboembolism (VTE) prescribed apixaban or rivaroxaban for the first time, the risk of recurrence with propensity score mapping was lower with apixaban (hazard ratio [HR] 0.77, 95% CI 0.69-0.87) [<a href="#rid76">76</a>]. There were 11.4 fewer events per 100 person-years with apixaban and an absolute difference in VTE recurrence at six months that was 0.011 lower with apixaban. Subgroup analysis did not show any difference in the findings. Bleeding (gastrointestinal and intracranial) was also lower with apixaban.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">Rivaroxaban</a> and <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a> are given once daily; <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> is given twice daily  (<a class="graphic graphic_table graphicRef112514" href="/z/d/graphic/112514.html" rel="external">table 5</a>). Rivaroxaban is given with food. For VTE, edoxaban is preceded by a parenteral agent; rivaroxaban and apixaban are preceded by a period of higher initial dosing. (See <a class="local">'Factor Xa inhibitors dosing'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Rivaroxaban appears to have a slightly higher risk of gastrointestinal bleeding. In a retrospective registry study involving over 5000 consecutive individuals taking apixaban or rivaroxaban (including all individuals who received a prescription for a DOAC in the country of Iceland), there were 241 gastrointestinal bleeding events, approximately one-half in the lower gastrointestinal tract (overall rate of gastrointestinal bleeding, approximately 4 percent) [<a href="#rid77">77</a>]. The bleeding rate was higher with rivaroxaban than apixaban (3.2 versus 2.5 per 100 person-years; HR 1.42, 95% CI 1.04-1.93). Similar findings were reported in previous population-based registry studies [<a href="#rid78">78</a>]. The higher bleeding risk with rivaroxaban may be related to the higher peak drug levels associated with once-daily dosing. A retrospective review of more than 37,000 adults with VTE who were prescribed apixaban or rivaroxaban showed less bleeding with <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> (absolute reduction in probability of gastrointestinal and intracranial bleeding within six months of starting apixaban versus rivaroxaban, 0.015, 95% CI 0.013-0.015) [<a href="#rid76">76</a>].</p><p></p><p class="headingAnchor" id="H1109703359"><span class="h3">Factor Xa inhibitors dosing</span><span class="headingEndMark"> — </span>Direct factor Xa inhibitors are administered at a fixed dose without monitoring. It is important to use the appropriate dose (do not under-dose). Anti-factor Xa activity can be measured in unusual circumstances (individual with altered gastrointestinal anatomy for whom there is concern about drug absorption, individual who must take an interacting drug along with a direct factor Xa inhibitor, individual with an extremely high body mass index [BMI]).</p><p>However, if drug levels or anti-factor Xa activity is used, the purpose should be to confirm that the drug is being absorbed and that levels are not excessive, rather than to target a therapeutic range, because there is no established therapeutic range for these drugs. For reasonable levels, the clinician must rely on guidance from their institutional laboratory, information from the manufacturer, and/or data from clinical trials [<a href="#rid61">61,79</a>]. If anti-factor Xa activity is tested, it ideally should be based on an assay calibrated for the specific anticoagulant. If an assay calibrated for the specific drug is not available, it may be possible to use an assay calibrated for heparin, although this approach has not been clinically validated [<a href="#rid80">80</a>]. Examples of typical expected drug levels are listed in the individual sections below.</p><p>Dose reduction is recommended for patients who are also receiving strong dual inhibitors of CYP-3A4 and P-glycoprotein; increased bleeding has been reported with apixaban in combination with fluconazole. (See <a class="local">'Dosing, monitoring, risks (apixaban)'</a> below.) </p><p>It may be reasonable to use a lower dose of rivaroxaban in some individuals with ancestry from countries in Asia, especially Japan. (See <a class="local">'Dosing, monitoring, risks (rivaroxaban)'</a> below.) </p><p>In a study of people from Korea, use of a lower dose of <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> for atrial fibrillation resulted in inferior efficacy compared with standard dosing [<a href="#rid81">81</a>]. (See <a class="local">'Dosing, monitoring, risks (apixaban)'</a> below.)</p><p class="headingAnchor" id="H2241514236"><span class="h3">Factor Xa inhibitors toxicity</span><span class="headingEndMark"> — </span>Direct factor Xa inhibitors are partially excreted by the kidney (approximately 25 to 35 percent) and metabolized in the liver; drug accumulation could occur with severe hepatic impairment. </p><p>Direct factor Xa inhibitors do not appear to cause hepatotoxicity. In a cohort study involving 51,887 patients receiving a DOAC (3778 of whom [7 percent] had prior liver disease), there was not an increased risk of serious liver injury (adjusted hazard ratio [HR] 0.99, 95% CI 0.68-1.45) [<a href="#rid73">73</a>]. In the individuals with prior liver disease, there was a trend towards a lower risk of serious liver injury with the DOACs that did not reach statistical significance (adjusted HR 0.68, 95% CI 0.33-1.37).</p><p>All factor Xa inhibitors increase the risk of bleeding, and each has a Boxed Warning regarding the risk of spinal/epidural hematoma in patients undergoing neuraxial anesthesia or spinal puncture and the risk of thrombotic events following premature discontinuation.</p><p>Treatment of bleeding is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants"</a>.)</p><p class="headingAnchor" id="H873814329"><span class="h3">High BMI and post-bariatric surgery</span><span class="headingEndMark"> — </span>Data are slowly accumulating demonstrating use of direct factor Xa inhibitors in individuals with a high body mass index (BMI). </p><p class="bulletIndent1"><span class="glyph">●</span><strong>High BMI</strong> – Based on a 2021 review of available literature, the International Society on Thrombosis and Haemostasis (ISTH) recommended that any DOAC is appropriate for individuals with BMI up to 40 kg/m<sup>2</sup> or weight 120 kg [<a href="#rid53">53</a>]. For individuals with a BMI &gt;40 kg/m<sup>2</sup>, or weight ≥120 kg with VTE, standard doses of <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> or <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> are appropriate anticoagulant options. </p><p></p><p class="bulletIndent1">A 2021 Guideline from the International Society on Thrombosis and Haemostasis (ISTH), 2017 review, and subsequent studies of rivaroxaban and <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> concluded that they could be administered to individuals with a BMI &gt;40 kg/m<sup>2</sup> (or weight &gt;120 kg) and even ≥50 kg/m<sup>2</sup> without dose adjustment, although data were limited [<a href="#rid53">53,82-84</a>]. (See <a class="local">'Dosing, monitoring, risks (rivaroxaban)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Post-bariatric surgery</strong> – Immediate postoperative VTE prophylaxis is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/88610.html" rel="external">"Bariatric surgery: Postoperative and long-term management", section on 'Venous thromboembolism'</a>.)</p><p></p><p class="bulletIndent1">Anticoagulant selection in individuals who have undergone bariatric surgery and require anticoagulation for another reason (atrial fibrillation, VTE) should incorporate available information on the effects of altered gastroduodenal anatomy on DOAC absorption. Absorption depends on which bariatric procedure was performed, as summarized in the table  (<a class="graphic graphic_table graphicRef135133" href="/z/d/graphic/135133.html" rel="external">table 8</a>). Apixaban absorption appears to be the least affected [<a href="#rid53">53</a>]. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">Apixaban</a> is likely to be reasonable post-bariatric surgery, especially if it is not in the immediate postoperative period. The 2021 ISTH Guideline suggests using a parenteral anticoagulant for immediate post-bariatric surgery VTE treatment (first few weeks) before switching to a DOAC and then checking a trough level to ensure absorption [<a href="#rid53">53</a>]. </p><p></p><p class="bulletIndent1">A 2023 retrospective study evaluated VTE risk in 102 adults who required anticoagulation for VTE following bariatric surgery and were treated with a DOAC [<a href="#rid85">85</a>]. Among individuals treated with <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a>, there were no VTE recurrences during a median of 137 days of observation. Among 60 individuals treated with <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a>, there was one VTE recurrence during a median of 240 days of observation. The individual had other risk factors for recurrence including chronic venous stasis, foot ulcers requiring a boot, and a BMI of 54 kg/m<sup>2</sup> at the time of the event. (See  <a class="medical medical_review" href="/z/d/html/88536.html" rel="external">"Bariatric procedures for the management of severe obesity: Descriptions"</a>.)</p><p></p><p class="headingAnchor" id="H20"><span class="h2">Rivaroxaban</span></p><p class="headingAnchor" id="H89175171"><span class="h3">Overview (rivaroxaban)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">Rivaroxaban</a> (Xarelto) is an oral direct factor Xa inhibitor with a half-life of 5 to 9 hours (may be longer in older individuals [eg, 11 to 13 hours]).</p><p>Rivaroxaban is used in the prevention and treatment of venous thromboembolic (VTE) disease, in stroke prevention in patients with atrial fibrillation (AF), and in ischemic heart disease. These indications are discussed in detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>VTE prophylaxis – (See  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>VTE overview of treatment – (See  <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>VTE initial treatment – (See  <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">"Venous thromboembolism: Initiation of anticoagulation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>VTE extended treatment – (See  <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">"Venous thromboembolism: Anticoagulation after initial management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>AF – (See  <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Ischemic heart disease – (See  <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk"</a> and  <a class="medical medical_review" href="/z/d/html/101.html" rel="external">"Acute coronary syndrome: Oral anticoagulation in medically treated patients"</a>.)</p><p></p><p>Rivaroxaban should not be used in individuals with mechanical prosthetic heart valves or during pregnancy. (See  <a class="medical medical_review" href="/z/d/html/8171.html" rel="external">"Antithrombotic therapy for mechanical heart valves"</a> and  <a class="medical medical_review" href="/z/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum"</a>.)</p><p class="headingAnchor" id="H14130832"><span class="h3">Dosing, monitoring, risks (rivaroxaban)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">Rivaroxaban</a> is generally given at a fixed dose without monitoring  (<a class="graphic graphic_table graphicRef112514" href="/z/d/graphic/112514.html" rel="external">table 5</a>). The 15 and 20 mg tablets used in adults are to be taken with food [<a href="#rid86">86,87</a>]. The dosing differs according to the clinical indication and the patient's kidney function. For patients from Japan, a lower dose (15 rather than 20 mg) has been validated for venous thromboembolism (VTE), secondary prevention, and atrial fibrillation (AF), and is supported by pharmacokinetic studies [<a href="#rid88">88-90</a>]. Studies from other regions in Asia (Taiwan, Thailand) appear to show similar findings, although sample sizes are smaller and more study is needed [<a href="#rid91">91,92</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>VTE prophylaxis in surgical patients – 10 mg daily; duration (12 days versus extended to 35 days) depends on the type of surgery, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1335.html" rel="external">"Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement"</a> and  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.)</p><p></p><p class="bulletIndent1">Use for VTE treatment in children is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5916.html" rel="external">"Venous thrombosis and thromboembolism (VTE) in children: Treatment, prevention, and outcome", section on 'Direct oral anticoagulants'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment and secondary prevention of VTE – 15 mg twice daily (with food) for 21 days, followed by 20 mg once daily (with food). Adequate treatment for VTE is full-dose anticoagulation for three to six months. If secondary prevention is considered after full-dose treatment, the dose can be reduced to 10 mg once daily for selected individuals. However, for those with an increased risk for VTE beyond six months of anticoagulation (eg, two or more episodes of VTE), the 20 mg once-daily dose should be used [<a href="#rid93">93</a>]. (See  <a class="medical medical_review" href="/z/d/html/94740.html" rel="external">"Selecting adult patients with lower extremity deep venous thrombosis and pulmonary embolism for indefinite anticoagulation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stroke prevention in AF – 20 mg once daily with the evening meal (creatinine clearance [CrCl] &gt;50 mL/minute); or 15 mg once daily with the evening meal (CrCl ≤50 mL/minute). (See  <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Secondary prevention in individuals with stable cardiovascular disease – 2.5 mg twice daily in combination with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>. (See  <a class="medical medical_review" href="/z/d/html/1505.html" rel="external">"Prevention of cardiovascular disease events in those with established disease (secondary prevention) or at very high risk", section on 'Anticoagulant therapy'</a>.)</p><p></p><p>Rivaroxaban is not recommended for VTE prophylaxis, treatment, or secondary prevention in individuals with a CrCl &lt;30 mL/minute. The drug should not be used in individuals with a CrCl &lt;15 mL/minute, as well as in those with significant hepatic impairment (Child-Pugh Class B and C with coagulopathy) [<a href="#rid94">94</a>]. CrCl can be estimated from the patient's sex, age, weight, and serum creatinine (<a class="calc calc_professional" href="/z/d/html/13496.html" rel="external">calculator 1</a> and <a class="calc calc_professional" href="/z/d/html/16104.html" rel="external">calculator 2</a>). A 2023 update of the American Geriatric Society Beers criteria advises avoiding <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> in adults ≥65 years and using a safer alternative [<a href="#rid28">28</a>]. Recommendations for individuals with a high BMI are listed above. (See <a class="local">'General considerations for direct factor Xa inhibitors'</a> above.)</p><p>Rivaroxaban interacts with drugs that are potent dual inhibitors of CYP-3A4 and P-glycoprotein (eg, systemic <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">ketoconazole</a>, <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">itraconazole</a>, <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a>, or <a class="drug drug_general" data-topicid="9871" href="/z/d/drug information/9871.html" rel="external">ritonavir</a>), and concurrent use is contraindicated by Canadian product information  (<a class="graphic graphic_table graphicRef112756" href="/z/d/graphic/112756.html" rel="external">table 6</a> and <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">table 9</a> and <a class="graphic graphic_table graphicRef73326" href="/z/d/graphic/73326.html" rel="external">table 7</a>) [<a href="#rid50">50</a>]. Drugs that inhibit CYP-3A4 but do not also inhibit P-glycoprotein (eg, <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a>, <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, and <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>) may also increase <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> effect, but to a lesser extent than dual inhibitors. Potent inducers of CYP-3A4 (eg, rifamycins, carbamazepine, St. John's wort) may reduce rivaroxaban's effects  (<a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">table 9</a>) [<a href="#rid95">95-97</a>].</p><p>Laboratory testing prior to initiating <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> should include platelet count, prothrombin time (PT), and activated partial thromboplastin time (aPTT), to assess and document coagulation status before anticoagulation; and measurement of serum creatinine and liver function tests, as a baseline and for potential dose adjustment in the event of impaired kidney or liver function.</p><p>Routine monitoring of coagulation times is not required for patients taking rivaroxaban, because drug levels are relatively predictable for a given dose, and there is no established therapeutic range. However, possible improvements in efficacy and/or safety with monitoring have been suggested [<a href="#rid59">59,60</a>].</p><p>If there is a concern that drug levels are abnormally low or abnormally high, it may be appropriate to test for the presence of the drug. A consensus document from the International Council for Standardization in Haematology (ICSH) has provided examples of rivaroxaban drug levels for the 20 mg once-daily dose, with an expected mean peak of approximately 250 to 270 ng/mL (5<sup>th</sup> to 95<sup>th</sup> percentile of 184 to 419 ng/mL) and an expected trough of approximately 26 to 44 ng/mL (5<sup>th</sup> to 95<sup>th</sup> percentile, 6 to 137 ng/mL) [<a href="#rid61">61</a>]. These values are intended to be used as guides to provide evidence of drug absorption, not as therapeutic targets.</p><p>Examples of settings in which coagulation testing for rivaroxaban effect may be helpful include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Bleeding in a patient receiving rivaroxaban, or with suspected rivaroxaban overdose – (See  <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants", section on 'Assessment of anticoagulation status'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Need for emergency or urgent surgery in a patient receiving rivaroxaban – (See  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants", section on 'Rivaroxaban'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concerns about absorption (eg, altered gastrointestinal anatomy) or drug adherence.</p><p></p><p>In such cases, testing is best done by measuring anti-factor Xa activity using an assay specifically calibrated for <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a>. </p><p>If an anti-factor Xa assay calibrated to rivaroxaban is not available, it may be possible (although not ideal) to use an anti-factor Xa assay calibrated to another anticoagulant such as low molecular weight (LMW) heparin. Other assays such as the PT and aPTT are not very reliable [<a href="#rid98">98</a>].</p><p>Cases of liver injury following rivaroxaban administration have been reported, although this was not seen in larger trials [<a href="#rid99">99,100</a>]. The incidence of this complication is unknown.</p><p>As with all anticoagulants, rivaroxaban increases bleeding risk and is administered in the setting of increased thrombotic risk. Product labeling for rivaroxaban has Boxed Warnings regarding the risk of spinal/epidural hematoma in patients undergoing neuraxial anesthesia or spinal puncture and the risk of thrombotic events following premature discontinuation [<a href="#rid101">101</a>]. (See  <a class="medical medical_review" href="/z/d/html/14930.html" rel="external">"Neuraxial anesthesia/analgesia techniques in the patient receiving anticoagulant or antiplatelet medication"</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Apixaban</span></p><p class="headingAnchor" id="H89175184"><span class="h3">Overview (apixaban)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">Apixaban</a> (Eliquis; generic formulations were approved in late 2019 [<a href="#rid102">102</a>]) is an oral direct factor Xa inhibitor with a half-life of approximately 12 hours. Among the direct factor Xa inhibitors, apixaban appears to have greater efficacy and safety in individuals with VTE, although the absolute differences were small. (See <a class="local">'Differences between factor Xa inhibitors'</a> above.) </p><p>Apixaban is used in the prevention and treatment of VTE and in stroke prevention in patients with AF. These indications are discussed in detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>VTE prophylaxis – (See  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>VTE overview of treatment – (See  <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>VTE initial treatment – (See  <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">"Venous thromboembolism: Initiation of anticoagulation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>VTE extended treatment – (See  <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">"Venous thromboembolism: Anticoagulation after initial management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>AF – (See  <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a>.)</p><p></p><p>Apixaban should not be used in patients with mechanical prosthetic heart valves or during pregnancy. (See  <a class="medical medical_review" href="/z/d/html/8171.html" rel="external">"Antithrombotic therapy for mechanical heart valves"</a> and  <a class="medical medical_review" href="/z/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum"</a>.)</p><p class="headingAnchor" id="H5818288"><span class="h3">Dosing, monitoring, risks (apixaban)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">Apixaban</a> is generally given at a fixed dose without monitoring  (<a class="graphic graphic_table graphicRef112514" href="/z/d/graphic/112514.html" rel="external">table 5</a>).</p><p>The dosing of apixaban differs according to the clinical indication and the patient's age, weight, and kidney function [<a href="#rid103">103</a>]. We do not reduce the dose for individuals from countries in Asia.</p><p class="bulletIndent1"><span class="glyph">●</span>Venous thromboembolism (VTE) prophylaxis in surgical patients: 2.5 mg twice daily; duration (12 days versus extended to 35 days) depends on the type of surgery, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1335.html" rel="external">"Prevention of venous thromboembolism in adults undergoing hip fracture repair or hip or knee replacement"</a> and  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment and secondary prevention of VTE: 10 mg twice daily for seven days, followed by 5 mg twice daily. Adequate treatment for VTE is full-dose anticoagulation for three to six months. If secondary prevention is considered after full-dose treatment, the dose is reduced to 2.5 mg twice daily, based on data from a randomized trial showing equivalent efficacy and reduced bleeding at the 2.5 mg twice-daily dose [<a href="#rid104">104</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stroke prevention in atrial fibrillation (AF): 5 mg twice daily (CrCl &gt;50 mL/minute); or 2.5 mg twice daily for those with any two of the following: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL.</p><p></p><p>Apixaban dose reduction is recommended for patients who are also receiving strong dual inhibitors of CYP-3A4 and P-glycoprotein  (<a class="graphic graphic_table graphicRef112756" href="/z/d/graphic/112756.html" rel="external">table 6</a> and <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">table 9</a> and <a class="graphic graphic_table graphicRef73326" href="/z/d/graphic/73326.html" rel="external">table 7</a>) [<a href="#rid103">103</a>]. </p><p>In a large registry series involving nearly 100,000 patients with atrial fibrillation who were taking a DOAC, use of apixaban and concurrent systemic <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>, a moderate inhibitor of CYP-3A4, was associated with an increased bleeding rate (case-crossover odds ratio [OR] for different 30-day exposure periods, 3.5, 95% CI 1.4-10.6) [<a href="#rid105">105</a>]. The main increase was in gastrointestinal bleeding requiring hospitalization (65 percent of bleeding with the drug combination versus 50 percent of bleeding with apixaban alone). Topical fluconazole was not associated with increased bleeding, and other DOACs did not have the same association when combined with systemic fluconazole. While moderate CYP-3A4 inhibitors such as fluconazole are not contraindicated and do not require routine dose reduction in patients taking <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a>, this study highlights the importance of possible drug interactions and of considering alternatives that might be equally effective, such as topical therapy.</p><p>Recommendations for individuals with a high BMI are listed above. (See <a class="local">'General considerations for direct factor Xa inhibitors'</a> above.)</p><p>Other than betrixaban, apixaban has the least dependence on clearance by the kidney. Canadian product information states that apixaban is not recommended in individuals with CrCl &lt;15 mL/minute; United States product information recommends dose adjustments based on CrCl, body weight, and age [<a href="#rid106">106,107</a>]. CrCl can be estimated from the patient's sex, age, weight, and serum creatinine (<a class="calc calc_professional" href="/z/d/html/13496.html" rel="external">calculator 1</a> and <a class="calc calc_professional" href="/z/d/html/16104.html" rel="external">calculator 2</a>).</p><p>Laboratory testing prior to initiating apixaban should include platelet count, PT, and aPTT, to assess and document coagulation status before anticoagulation; and measurement of serum creatinine and liver function tests, as a baseline and for potential dose adjustment in the event of decreased kidney or liver function.</p><p>Routine monitoring of coagulation times is not required for patients taking apixaban because drug levels are relatively predictable for a given dose and there is no established therapeutic range. However, possible improvements in efficacy and/or safety with monitoring have been suggested [<a href="#rid59">59,60</a>].</p><p>If there is a concern that apixaban drug levels are abnormally low or abnormally high, it may be appropriate to test for the presence of the drug. A consensus document from the International Council for Standardization in Haematology (ICSH) has provided examples of apixaban drug levels for the 5 mg twice-daily dose, with an expected median peak of approximately 171 to 132 ng/mL (5<sup>th</sup> to 95<sup>th</sup> percentile of 59 to 321 ng/mL) and an expected trough of approximately 63 to 103 ng/mL (5<sup>th</sup> to 95<sup>th</sup> percentile, 22 to 230 ng/mL) [<a href="#rid61">61</a>]. These values are intended to be used as guides to provide evidence of drug absorption, not as therapeutic targets.</p><p>Settings in which coagulation testing for <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> effect may be helpful include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Bleeding in a patient receiving apixaban or with suspected apixaban overdose – (See  <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants", section on 'Assessment of anticoagulation status'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Need for emergency or urgent surgery in a patient receiving apixaban – (See  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants", section on 'Apixaban'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concerns about absorption (eg, altered gastrointestinal anatomy) or drug adherence.</p><p></p><p>In such cases, anti-factor Xa activity can be measured [<a href="#rid108">108</a>].</p><p>As with all anticoagulants, apixaban increases bleeding risk and is administered in the setting of increased thromboembolic risk. Product labeling for <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> has Boxed Warnings regarding the risk of spinal/epidural hematoma in patients undergoing neuraxial anesthesia or spinal puncture and the risk of thrombotic events following premature discontinuation [<a href="#rid103">103</a>].</p><p class="headingAnchor" id="H1492700"><span class="h2">Edoxaban</span></p><p class="headingAnchor" id="H4182212657"><span class="h3">Overview (edoxaban)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">Edoxaban</a> (Lixiana, Savaysa) is an oral direct factor Xa inhibitor with a half-life in the range of 10 to 14 hours.</p><p>Edoxaban is used in the prevention and treatment of VTE and in stroke prevention in patients with AF. These indications are discussed in detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>VTE prophylaxis – (See  <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">"Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>VTE overview of treatment – (See  <a class="medical medical_review" href="/z/d/html/1362.html" rel="external">"Overview of the treatment of proximal and distal lower extremity deep vein thrombosis (DVT)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>VTE initial treatment – (See  <a class="medical medical_review" href="/z/d/html/95336.html" rel="external">"Venous thromboembolism: Initiation of anticoagulation"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>VTE extended treatment – (See  <a class="medical medical_review" href="/z/d/html/95395.html" rel="external">"Venous thromboembolism: Anticoagulation after initial management"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>AF – (See  <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a>.)</p><p></p><p>Edoxaban should not be used in patients with mechanical prosthetic heart valves or during pregnancy. (See  <a class="medical medical_review" href="/z/d/html/8171.html" rel="external">"Antithrombotic therapy for mechanical heart valves"</a> and  <a class="medical medical_review" href="/z/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum"</a>.)</p><p class="headingAnchor" id="H2766643685"><span class="h3">Dosing, monitoring, risks (edoxaban)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">Edoxaban</a> is generally given at a fixed dose without monitoring  (<a class="graphic graphic_table graphicRef112514" href="/z/d/graphic/112514.html" rel="external">table 5</a>). Absorption is unaffected by food. For patients being treated for VTE, edoxaban is given after 5 to 10 days of parenteral anticoagulation. Typical dosing is 30 or 60 mg orally once daily [<a href="#rid109">109-112</a>]. A reduced dose of 15 mg once daily has been proposed for Japanese individuals with atrial fibrillation who are ≥80 years of age and are not considered to be candidates for standard-dose therapy [<a href="#rid113">113</a>]. Recommendations for individuals with a high BMI are listed above. (See <a class="local">'General considerations for direct factor Xa inhibitors'</a> above.)</p><p>Edoxaban is excreted by the kidney and is a substrate for P-glycoprotein. Product labeling has a Boxed Warning regarding reduced efficacy in nonvalvular atrial fibrillation in patients with a high CrCl (&gt;95 mL/minute) [<a href="#rid114">114</a>]. Product information advises dose reduction for people with CrCl of 15 to 50 mL/minute, and <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a> is not to be used in those with CrCl &gt;95 mL/minute or &lt;15 mL/minute  (<a class="graphic graphic_table graphicRef112756" href="/z/d/graphic/112756.html" rel="external">table 6</a>) [<a href="#rid115">115</a>]. CrCl can be estimated from the patient's sex, age, weight, and serum creatinine (<a class="calc calc_professional" href="/z/d/html/13496.html" rel="external">calculator 1</a> and <a class="calc calc_professional" href="/z/d/html/16104.html" rel="external">calculator 2</a>).</p><p>Laboratory testing prior to initiating edoxaban should include platelet count, PT, and aPTT, to assess and document coagulation status before anticoagulation; and measurement of serum creatinine and liver function tests, as a baseline and for potential dose adjustment in the event of decreased kidney or liver function.</p><p>Routine monitoring of coagulation times is not required for patients taking edoxaban because drug levels are relatively predictable for a given dose and there is no established therapeutic range. Possible improvements in efficacy and/or safety with monitoring have been suggested [<a href="#rid59">59</a>]. </p><p>If there is a concern that edoxaban drug levels are abnormally low or abnormally high, it may be appropriate to test for the presence of the drug. A consensus document from the International Council for Standardization in Haematology (ICSH) has provided examples of <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a> drug levels for the 60 mg once-daily dose, with an expected median peak of approximately 170 to 234 ng/mL (interquartile range [IQR], 125 to 317 ng/mL) and an expected trough of approximately 19 to 36 ng/mL (IQR, 10 to 62 ng/mL) [<a href="#rid61">61</a>]. These values are intended to be used as guides to provide evidence of drug absorption, not as therapeutic targets.</p><p>Settings in which coagulation testing for edoxaban effect may be helpful include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Bleeding in a patient receiving edoxaban or with suspected <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">edoxaban</a> overdose – (See  <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants", section on 'Assessment of anticoagulation status'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Need for emergency or urgent surgery in a patient receiving edoxaban – (See  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants", section on 'Edoxaban'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concerns about absorption (eg, altered gastrointestinal anatomy) or drug adherence.</p><p></p><p>As with all anticoagulants, edoxaban increases bleeding risk and is administered in the setting of increased thrombotic risk. Product labeling for edoxaban has Boxed Warnings regarding the risk of spinal/epidural hematoma in patients undergoing neuraxial anesthesia or spinal puncture, the risk of thrombotic events following premature discontinuation [<a href="#rid114">114</a>].</p><p class="headingAnchor" id="H1254006807"><span class="h2">Betrixaban</span><span class="headingEndMark"> — </span>Betrixaban (Bevyxxa) was an oral direct factor Xa inhibitor with a half-life in the range of 19 to 27 hours [<a href="#rid116">116</a>]. It was discontinued in the United States in 2020 (for business reasons) and was not marketed in other countries.</p><p class="headingAnchor" id="H3776109419"><span class="h1">TRANSITIONING BETWEEN ANTICOAGULANTS</span><span class="headingEndMark"> — </span>The goal when transitioning between anticoagulants is to maintain stable anticoagulation. </p><p>When transitioning <strong>from</strong> a DOAC <strong>to</strong> a vitamin K antagonist (VKA), it is important to keep in mind that the full effect of the VKA does not occur for the first few days, despite prolongation of the prothrombin time/international normalized ratio (PT/INR) [<a href="#rid117">117,118</a>] (see  <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects", section on 'Initial dosing'</a>). Likewise, when transitioning from <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> to a DOAC, the resolution of warfarin effect may take several days.</p><p>Approaches to switching between oral anticoagulants, summarized in the table  (<a class="graphic graphic_table graphicRef120639" href="/z/d/graphic/120639.html" rel="external">table 10</a>) and discussed in the following sections, are derived from the drug package inserts and a 2018 clinical practice guideline from the American Society of Hematology (ASH) [<a href="#rid119">119</a>]. These are reasonable approaches when switching between anticoagulants but do not substitute for clinical judgment regarding individual patient factors.</p><p>Aspects of anticoagulant transitioning specific to individuals with prosthetic heart valves and in the perioperative setting are discussed in detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prosthetic heart valve</strong> – (See  <a class="medical medical_review" href="/z/d/html/104830.html" rel="external">"Anticoagulation for prosthetic heart valves: Management of bleeding and invasive procedures", section on 'Planning for invasive procedures'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Perioperative management</strong> – (See  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a>.)</p><p></p><p class="headingAnchor" id="H643694235"><span class="h2">From a DOAC to warfarin or another DOAC</span><span class="headingEndMark"> — </span>The full effect of the VKA does not occur for the first few days, despite prolongation of the prothrombin time/international normalized ratio (PT/INR) [<a href="#rid117">117,118</a>]. (See  <a class="medical medical_review" href="/z/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects", section on 'Initial dosing'</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dabigatran</strong><strong> to </strong><strong>warfarin</strong> – The two agents are overlapped [<a href="#rid120">120</a>]. The number of days of overlap depends on the patient's kidney function:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Creatinine clearance (CrCl) ≥50 mL/minute – Start VKA three days before discontinuing <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a>.</p><p class="bulletIndent2"><span class="glyph">•</span>CrCl 30 to 50 mL/minute – Start VKA two days before discontinuing <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a>.</p><p class="bulletIndent2"><span class="glyph">•</span>CrCl 15 to 30 mL/minute – Start VKA one day before discontinuing <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">dabigatran</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rivaroxaban</strong><strong> to </strong><strong>warfarin</strong> – Prescribing information suggests stopping rivaroxaban and providing a parenteral agent during warfarin initiation, because the INR cannot be monitored adequately during administration of a direct factor Xa inhibitor [<a href="#rid86">86</a>]. Warfarin can be started at the same time as the parenteral agent or afterwards, whichever is more appropriate for the patient's final warfarin schedule.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Apixaban</strong><strong> to </strong><strong>warfarin</strong> – Prescribing information suggests stopping apixaban and providing a parenteral agent during warfarin initiation because the INR cannot be monitored adequately during administration of a direct factor Xa inhibitor [<a href="#rid121">121</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Edoxaban</strong><strong> to </strong><strong>warfarin</strong> – For patients taking 60 mg of edoxaban, reduce the dose to 30 mg and begin the VKA concomitantly [<a href="#rid122">122</a>]. For patients receiving 30 mg of edoxaban, reduce the dose to 15 mg and begin the VKA concomitantly. The INR must be measured at least weekly and just prior to the daily dose of edoxaban to minimize the effect of edoxaban on INR measurements. Discontinue edoxaban once a stable increased INR (ie, INR ≥2 for at least two days) is reached.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>DOAC to another DOAC</strong> – When switching from one DOAC to another DOAC, no overlap is needed. The second DOAC is started when the next dose of the first DOAC would have been due.</p><p></p><p>Alternative approaches for transitioning from a direct factor Xa inhibitor to warfarin based on the pharmacodynamics of warfarin and the other anticoagulant might be reasonable. The ASH guideline suggests overlapping the two anticoagulants until the INR is therapeutic on warfarin [<a href="#rid119">119</a>]; two to three days of overlap with a therapeutic INR may be appropriate because the PT/INR will enter the therapeutic range <strong>before</strong> full anticoagulation occurs.</p><p>The direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) also prolong the PT/INR, which may make monitoring during the transition more challenging. Thus, when possible, the ASH guideline specifies that testing be done right before the next dose of the factor Xa inhibitor to minimize this interference [<a href="#rid119">119</a>].</p><p class="headingAnchor" id="H413990974"><span class="h2">From a VKA to a DOAC or argatroban</span><span class="headingEndMark"> — </span>When switching from a VKA to a DOAC, the resolution of <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> effect may take several days. The product-specific package inserts differ slightly, but in general we think it is reasonable to discontinue the VKA and initiate the DOAC when the INR is ≤2:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Warfarin</strong><strong> to </strong><strong>argatroban</strong> – Start argatroban when the INR is &lt;2. (See  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants", section on 'Bridging anticoagulation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Warfarin</strong><strong> to </strong><strong>dabigatran</strong> – Discontinue the VKA, monitor the PT/INR, and start dabigatran when the PT/INR is &lt;2 [<a href="#rid120">120</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Warfarin</strong><strong> to </strong><strong>rivaroxaban</strong> – Discontinue the VKA, monitor the PT/INR, and start rivaroxaban when the PT/INR is &lt;3 [<a href="#rid123">123</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Warfarin</strong><strong> to </strong><strong>apixaban</strong> – Discontinue the VKA, monitor the PT/INR, and start apixaban when the PT/INR is &lt;2 [<a href="#rid124">124</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Warfarin</strong><strong> to </strong><strong>edoxaban</strong> – Discontinue the VKA, monitor the PT/INR, and start edoxaban when the PT/INR is ≤2.5 [<a href="#rid122">122</a>].</p><p></p><p>Switching from a parenteral direct thrombin inhibitor to <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> is discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8765" href="/z/d/drug information/8765.html" rel="external">Argatroban</a> to <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> – (See  <a class="medical medical_review" href="/z/d/html/1369.html" rel="external">"Management of heparin-induced thrombocytopenia", section on 'Transition to warfarin or other outpatient anticoagulant'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">Bivalirudin</a> to <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> – (See  <a class="medical medical_review" href="/z/d/html/92.html" rel="external">"Acute ST-elevation myocardial infarction: Management of anticoagulation"</a> and  <a class="medical medical_review" href="/z/d/html/93.html" rel="external">"Anticoagulant therapy in non-ST elevation acute coronary syndromes", section on 'Unfractionated heparin compared with bivalirudin'</a>.)</p><p></p><p class="headingAnchor" id="H1427702022"><span class="h2">Between DOACs and heparins</span><span class="headingEndMark"> — </span>(See  <a class="medical medical_review" href="/z/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects", section on 'Transitioning between anticoagulants'</a>.)</p><p class="headingAnchor" id="H4041298809"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/114614.html" rel="external">"Society guideline links: Anticoagulation"</a>.)</p><p class="headingAnchor" id="H285825769"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16265.html" rel="external">"Patient education: Choosing an oral medicine for blood clots (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/86638.html" rel="external">"Patient education: Taking oral medicines for blood clots (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H33"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biology</strong> – The direct thrombin inhibitors and direct factor Xa inhibitors act at points in the coagulation cascade that appear to be rate-limiting in clot formation  (<a class="graphic graphic_figure graphicRef94856" href="/z/d/graphic/94856.html" rel="external">figure 3</a>). They inactivate both circulating and clot-bound activated coagulation factors, and they do not induce antiplatelet antibodies. A major advantage is the lack of requirement for monitoring, due to less variability in drug effect for a given dose. There may be a lower risk of osteoporosis with direct oral anticoagulants (DOACs). However, DOACs are expensive, their half-lives are short, they are not appropriate for all indications, their dosages cannot be titrated to modify anticoagulation intensity, and adherence is more difficult to monitor than vitamin K antagonists. (See <a class="local">'Mechanisms of action and terminology'</a> above and <a class="local">'Comparison with heparin and warfarin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications </strong>– Indications for these agents are discussed in detail separately. Their use is not appropriate in patients with severely reduced kidney function, severe liver disease  (<a class="graphic graphic_table graphicRef117823" href="/z/d/graphic/117823.html" rel="external">table 3</a>), pregnancy, antiphospholipid syndrome (APS), or mechanical prosthetic heart valves. (See <a class="local">'Indications and contraindications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Parenteral agents</strong> – Parenteral direct thrombin inhibitors (DTIs) include <a class="drug drug_general" data-topicid="8792" href="/z/d/drug information/8792.html" rel="external">bivalirudin</a> (Angiomax) and <a class="drug drug_general" data-topicid="8765" href="/z/d/drug information/8765.html" rel="external">argatroban</a> (Argatra, Novastan, Arganova, Exembol). These have very short half-lives and specific clinical indications such as percutaneous coronary intervention (PCI) and heparin-induced thrombocytopenia (HIT). There are no parenteral direct factor Xa inhibitors. (See <a class="local">'Parenteral direct thrombin inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oral agents</strong> – These are generally administered at fixed doses without laboratory monitoring  (<a class="graphic graphic_table graphicRef112514" href="/z/d/graphic/112514.html" rel="external">table 5</a>). Dose adjustments for liver disease are presented in the table  (<a class="graphic graphic_table graphicRef117823" href="/z/d/graphic/117823.html" rel="external">table 3</a>). </p><p></p><p class="bulletIndent1">Laboratory testing prior to administration should include prothrombin time (PT) and activated partial thromboplastin time (aPTT), to assess and document coagulation status before anticoagulation; and measurement of serum creatinine, as a baseline and for potential dose adjustment in the event of reduced kidney function. Patients with impaired kidney function should have appropriate dose reduction or drug avoidance depending on the creatinine clearance. (See <a class="local">'Dabigatran'</a> above and <a class="local">'Direct factor Xa inhibitors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dabigatran (Pradaxa) is the only orally active DTI. It must be stored in the original blister pack with desiccant and not crushed. Dosing differs in the United States versus Europe. Dose reductions are used in impaired kidney function and with concomitant P-glycoprotein inducers or inhibitors  (<a class="graphic graphic_table graphicRef112756" href="/z/d/graphic/112756.html" rel="external">table 6</a> and <a class="graphic graphic_table graphicRef73326" href="/z/d/graphic/73326.html" rel="external">table 7</a>). Risks include bleeding, thrombosis upon discontinuation, and dyspepsia. (See <a class="local">'Dabigatran'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Orally active direct factor Xa inhibitors include rivaroxaban (Xarelto), apixaban (Eliquis), and edoxaban (Lixiana, Savaysa). <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">Rivaroxaban</a> is administered once daily and <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">apixaban</a> twice daily; they interact with drugs that are potent inhibitors of both CYP-3A4 and P-glycoprotein  (<a class="graphic graphic_table graphicRef112756" href="/z/d/graphic/112756.html" rel="external">table 6</a> and <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">table 9</a> and <a class="graphic graphic_table graphicRef73326" href="/z/d/graphic/73326.html" rel="external">table 7</a>). <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">Edoxaban</a> is administered once daily; it is excreted by the kidney and is a substrate for P-glycoprotein. Risks include bleeding, and thrombosis upon discontinuation. (See <a class="local">'Direct factor Xa inhibitors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transitioning between anticoagulants</strong> – The goal is to maintain stable anticoagulation. When transitioning between a DOAC and a vitamin K antagonist (VKA; eg, warfarin), keep in mind that the full effect of the VKA does not occur for the first few days. When transitioning from a VKA to a DOAC, keep in mind that the resolution of VKA effect may take several days. Specific recommendations are summarized in the table  (<a class="graphic graphic_table graphicRef120639" href="/z/d/graphic/120639.html" rel="external">table 10</a>) and discussed above. (See <a class="local">'Transitioning between anticoagulants'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Investigational approaches </strong>– (See  <a class="medical medical_review" href="/z/d/html/138700.html" rel="external">"Investigational anticoagulants"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bleeding</strong> – All anticoagulants increase bleeding risk. Management and prevention are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/119889.html" rel="external">"Risks and prevention of bleeding with oral anticoagulants"</a> and  <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants"</a> and  <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Di Nisio M, Middeldorp S, Büller HR. Direct thrombin inhibitors. N Engl J Med 2005; 353:1028.</a></li><li><a class="nounderline abstract_t">Rydel TJ, Ravichandran KG, Tulinsky A, et al. The structure of a complex of recombinant hirudin and human alpha-thrombin. Science 1990; 249:277.</a></li><li><a class="nounderline abstract_t">Grütter MG, Priestle JP, Rahuel J, et al. Crystal structure of the thrombin-hirudin complex: a novel mode of serine protease inhibition. EMBO J 1990; 9:2361.</a></li><li><a class="nounderline abstract_t">Hirsh J, Weitz JI. New antithrombotic agents. Lancet 1999; 353:1431.</a></li><li><a class="nounderline abstract_t">Hall SW, Nagashima M, Zhao L, et al. Thrombin interacts with thrombomodulin, protein C, and thrombin-activatable fibrinolysis inhibitor via specific and distinct domains. J Biol Chem 1999; 274:25510.</a></li><li><a class="nounderline abstract_t">Sheehan JP, Sadler JE. Molecular mapping of the heparin-binding exosite of thrombin. Proc Natl Acad Sci U S A 1994; 91:5518.</a></li><li><a class="nounderline abstract_t">Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86:385.</a></li><li><a class="nounderline abstract_t">Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J 2008; 29:155.</a></li><li><a class="nounderline abstract_t">Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin. Thromb Haemost 1994; 72:381.</a></li><li><a class="nounderline abstract_t">Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994; 90:1522.</a></li><li><a class="nounderline abstract_t">Laux V, Perzborn E, Heitmeier S, et al. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy? Thromb Haemost 2009; 102:892.</a></li><li><a class="nounderline abstract_t">Roehrig S, Straub A, Pohlmann J, et al. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 2005; 48:5900.</a></li><li><a class="nounderline abstract_t">Samama MM. The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants. Thromb Res 2011; 127:497.</a></li><li><a class="nounderline abstract_t">Ansell J, Crowther M, Burnett A, et al. Comment on: editorial by Husted et al. "Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel". (Thromb Haemost 2014; 111: 781-782). Thromb Haemost 2014; 112:841.</a></li><li><a class="nounderline abstract_t">Husted S, Lip GY, ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease. Response to Ansell et al. "Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel". (Thromb Haemost 2014; 112: 841). Thromb Haemost 2014; 112:842.</a></li><li><a class="nounderline abstract_t">Husted S, de Caterina R, Andreotti F, et al. Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost 2014; 111:781.</a></li><li><a class="nounderline abstract_t">Barnes GD, Ageno W, Ansell J, et al. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13:1154.</a></li><li><a class="nounderline abstract_t">Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood 2012; 119:3016.</a></li><li><a class="nounderline abstract_t">Trujillo-Santos J, Di Micco P, Dentali F, et al. Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens. Thromb Haemost 2017; 117:382.</a></li><li><a class="nounderline abstract_t">Arbel R, Sergienko R, Hammerman A, et al. Effectiveness and Safety of Off-Label Dose-Reduced Direct Oral Anticoagulants in Atrial Fibrillation. Am J Med 2019; 132:847.</a></li><li><a class="nounderline abstract_t">Ha JT, Neuen BL, Cheng LP, et al. Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis. Ann Intern Med 2019; 171:181.</a></li><li><a class="nounderline abstract_t">Cheung CYS, Parikh J, Farrell A, et al. Direct Oral Anticoagulant Use in Chronic Kidney Disease and Dialysis Patients With Venous Thromboembolism: A Systematic Review of Thrombosis and Bleeding Outcomes. Ann Pharmacother 2021; 55:711.</a></li><li><a class="nounderline abstract_t">Gladstone DJ, Geerts WH, Douketis J, et al. How to Monitor Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Practice Tool Endorsed by Thrombosis Canada, the Canadian Stroke Consortium, the Canadian Cardiovascular Pharmacists Network, and the Canadian Cardiovascular Society. Ann Intern Med 2015; 163:382.</a></li><li><a class="nounderline abstract_t">Chatterjee S, Sardar P, Giri JS, et al. Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients. Mayo Clin Proc 2014; 89:896.</a></li><li><a class="nounderline abstract_t">Shore S, Ho PM, Lambert-Kerzner A, et al. Site-level variation in and practices associated with dabigatran adherence. JAMA 2015; 313:1443.</a></li><li><a class="nounderline abstract_t">Chai-Adisaksopha C, Hillis C, Isayama T, et al. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost 2015; 13:2012.</a></li><li><a class="nounderline abstract_t">Mannucci PM. Thromboprophylaxis in the oldest old with atrial fibrillation: between Scylla and Charybdis. Eur J Intern Med 2013; 24:285.</a></li><li><a class="nounderline abstract_t">By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2023; 71:2052.</a></li><li><a class="nounderline abstract_t">Lutsey PL, Norby FL, Ensrud KE, et al. Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation. JAMA Intern Med 2020; 180:245.</a></li><li><a class="nounderline abstract_t">Huang HK, Liu PP, Hsu JY, et al. Fracture risks among patients with atrial fibrillation receiving different oral anticoagulants: a real-world nationwide cohort study. Eur Heart J 2020; 41:1100.</a></li><li><a class="nounderline abstract_t">Lau WC, Chan EW, Cheung CL, et al. Association Between Dabigatran vs Warfarin and Risk of Osteoporotic Fractures Among Patients With Nonvalvular Atrial Fibrillation. JAMA 2017; 317:1151.</a></li><li><a class="nounderline abstract_t">Lau WCY, Wong ICK, Chan EW. Osteoporotic Fractures Associated With Dabigatran vs Warfarin-Reply. JAMA 2017; 318:91.</a></li><li><a class="nounderline abstract_t">Sugiyama T. Osteoporotic Fractures Associated With Dabigatran vs Warfarin. JAMA 2017; 318:90.</a></li><li><a class="nounderline abstract_t">Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:141S.</a></li><li><a class="nounderline abstract_t">Eitzman DT, Chi L, Saggin L, et al. Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4. Circulation 1994; 89:1523.</a></li><li class="breakAll">http://www.angiomax.com/downloads/Angiomax_US_PI_June_2013.pdf (Accessed on September 03, 2014).</li><li><a class="nounderline abstract_t">Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost 2008; 99:830.</a></li><li><a class="nounderline abstract_t">Clarke RJ, Mayo G, FitzGerald GA, Fitzgerald DJ. Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation 1991; 83:1510.</a></li><li class="breakAll">https://www.gsksource.com/gskprm/htdocs/documents/ARGATROBAN.PDF (Accessed on September 03, 2014).</li><li><a class="nounderline abstract_t">Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20:318.</a></li><li class="breakAll">http://www.clinicaltrials.gov/ct2/results?term=AZD-0837 (Accessed on September 04, 2014).</li><li><a class="nounderline abstract_t">Hauel NH, Nar H, Priepke H, et al. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem 2002; 45:1757.</a></li><li class="breakAll">http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022512s028lbl.pdf (Accessed on November 30, 2015).</li><li class="breakAll">http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&amp;folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf (Accessed on September 04, 2014).</li><li><a class="nounderline abstract_t">van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103:1116.</a></li><li><a class="nounderline abstract_t">Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49:259.</a></li><li><a class="nounderline abstract_t">Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36:386.</a></li><li class="breakAll">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf (Accessed on September 04, 2014).</li><li><a class="nounderline abstract_t">Gulseth MP, Wittkowsky AK, Fanikos J, et al. Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness. Pharmacotherapy 2011; 31:1232.</a></li><li class="breakAll">http://webprod.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&amp;code=84384 (Accessed on March 23, 2011).</li><li class="breakAll">http://www.medicines.org.uk/EMC/medicine/20759/SPC/Pradaxa+75+mg+hard+capsules/ (Accessed on March 23, 2011).</li><li class="breakAll">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf (Accessed on March 23, 2011).</li><li><a class="nounderline abstract_t">Martin KA, Beyer-Westendorf J, Davidson BL, et al. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost 2021; 19:1874.</a></li><li><a class="nounderline abstract_t">Chan NC, Coppens M, Hirsh J, et al. Real-world variability in dabigatran levels in patients with atrial fibrillation. J Thromb Haemost 2015; 13:353.</a></li><li><a class="nounderline abstract_t">Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014; 63:321.</a></li><li><a class="nounderline abstract_t">Rao RB. Regarding the effect of dabigatran plasma concentrations. J Am Coll Cardiol 2014; 63:2885.</a></li><li><a class="nounderline abstract_t">Reilly PA, Connolly SJ, Yusuf S, et al. Reply: regarding the effect of dabigatran plasma concentrations. J Am Coll Cardiol 2014; 63:2885.</a></li><li><a class="nounderline abstract_t">Moore TJ, Cohen MR, Mattison DR. Dabigatran, bleeding, and the regulators. BMJ 2014; 349:g4517.</a></li><li><a class="nounderline abstract_t">Powell JR. Are new oral anticoagulant dosing recommendations optimal for all patients? JAMA 2015; 313:1013.</a></li><li><a class="nounderline abstract_t">Chan N, Sager PT, Lawrence J, et al. Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants? Am Heart J 2018; 199:59.</a></li><li><a class="nounderline abstract_t">Gosselin RC, Adcock DM, Bates SM, et al. International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thromb Haemost 2018; 118:437.</a></li><li><a class="nounderline abstract_t">Dager WE, Gosselin RC, Kitchen S, Dwyre D. Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study. Ann Pharmacother 2012; 46:1627.</a></li><li><a class="nounderline abstract_t">van Ryn J, Baruch L, Clemens A. Interpretation of point-of-care INR results in patients treated with dabigatran. Am J Med 2012; 125:417.</a></li><li class="breakAll">http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&amp;folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf (Accessed on September 03, 2014).</li><li class="breakAll">http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm282820.htm (Accessed on November 07, 2012).</li><li><a class="nounderline abstract_t">Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013; 368:1272.</a></li><li class="breakAll">http://www.fda.gov/Drugs/DrugSafety/ucm396470.htm (Accessed on May 14, 2014).</li><li><a class="nounderline abstract_t">Desai J, Kolb JM, Weitz JI, Aisenberg J. Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies. Thromb Haemost 2013; 110:205.</a></li><li><a class="nounderline abstract_t">Schulman S, Shortt B, Robinson M, Eikelboom JW. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemost 2013; 11:1295.</a></li><li><a class="nounderline abstract_t">Cheng JW, Vu H. Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders. Clin Ther 2012; 34:766.</a></li><li><a class="nounderline abstract_t">Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139.</a></li><li><a class="nounderline abstract_t">Bytzer P, Connolly SJ, Yang S, et al. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol 2013; 11:246.</a></li><li><a class="nounderline abstract_t">Douros A, Azoulay L, Yin H, et al. Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Serious Liver Injury. J Am Coll Cardiol 2018; 71:1105.</a></li><li><a class="nounderline abstract_t">Guertin KR, Choi YM. The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development. Curr Med Chem 2007; 14:2471.</a></li><li><a class="nounderline abstract_t">Steg PG, Mehta SR, Pollack CV Jr, et al. Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. JAMA 2013; 310:1145.</a></li><li><a class="nounderline abstract_t">Dawwas GK, Leonard CE, Lewis JD, Cuker A. Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data. Ann Intern Med 2022; 175:20.</a></li><li><a class="nounderline abstract_t">Ingason AB, Hreinsson JP, Ágústsson AS, et al. Rivaroxaban Is Associated With Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants : A Nationwide Propensity Score-Weighted Study. Ann Intern Med 2021; 174:1493.</a></li><li><a class="nounderline abstract_t">Fralick M, Colacci M, Schneeweiss S, et al. Effectiveness and Safety of Apixaban Compared With Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice: A Cohort Study. Ann Intern Med 2020; 172:463.</a></li><li><a class="nounderline abstract_t">Garcia D, Barrett YC, Ramacciotti E, Weitz JI. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost 2013; 11:245.</a></li><li><a class="nounderline abstract_t">Beyer J, Trujillo T, Fisher S, et al. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors. Clin Appl Thromb Hemost 2016; 22:423.</a></li><li><a class="nounderline abstract_t">Cho MS, Yun JE, Park JJ, et al. Outcomes After Use of Standard- and Low-Dose Non-Vitamin K Oral Anticoagulants in Asian Patients With Atrial Fibrillation. Stroke 2019; 50:110.</a></li><li><a class="nounderline abstract_t">Moore KT, Kröll D. Influences of Obesity and Bariatric Surgery on the Clinical and Pharmacologic Profile of Rivaroxaban. Am J Med 2017; 130:1024.</a></li><li><a class="nounderline abstract_t">O'Kane CP, Avalon JCO, Lacoste JL, et al. Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m2. Pharmacotherapy 2022; 42:112.</a></li><li><a class="nounderline abstract_t">Crouch A, Ng TH, Kelley D, et al. Multi-center retrospective study evaluating the efficacy and safety of apixaban versus warfarin for treatment of venous thromboembolism in patients with severe obesity. Pharmacotherapy 2022; 42:119.</a></li><li><a class="nounderline abstract_t">Kushnir M, Gali R, Alexander M, Billett HH. Direct oral Xa inhibitors for the treatment of venous thromboembolism after bariatric surgery. Blood Adv 2023; 7:224.</a></li><li class="breakAll">http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022406s004lbl.pdf (Accessed on June 02, 2015).</li><li><a class="nounderline abstract_t">Beyer-Westendorf J, Siegert G. Of men and meals. J Thromb Haemost 2015; 13:943.</a></li><li><a class="nounderline abstract_t">Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –. Circ J 2012; 76:2104.</a></li><li><a class="nounderline abstract_t">Tanigawa T, Kaneko M, Hashizume K, et al. Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation. Drug Metab Pharmacokinet 2013; 28:59.</a></li><li><a class="nounderline abstract_t">Kaneko M, Tanigawa T, Hashizume K, et al. Confirmation of model-based dose selection for a Japanese phase III study of rivaroxaban in non-valvular atrial fibrillation patients. Drug Metab Pharmacokinet 2013; 28:321.</a></li><li><a class="nounderline abstract_t">Chan YH, Lee HF, Wang CL, et al. Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J-ROCKET AF Trials) in Asian Patients With Atrial Fibrillation. J Am Heart Assoc 2019; 8:e013053.</a></li><li><a class="nounderline abstract_t">Okumura Y, Fukuda I, Nakamura M, et al. A Multicenter Prospective Observational Cohort Study to Investigate the Effectiveness and Safety of Rivaroxaban in Japanese Venous Thromboembolism Patients (The J'xactly Study). Circ J 2020; 84:1912.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022406s024lbl.pdf (Accessed on November 01, 2017).</li><li><a class="nounderline abstract_t">Poulsen BK, Grove EL, Husted SE. New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs 2012; 72:1739.</a></li><li><a class="nounderline abstract_t">Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 2011; 31:326.</a></li><li><a class="nounderline abstract_t">Eikelboom JW, Weitz JI. New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty. BMJ 2011; 342:c7270.</a></li><li><a class="nounderline abstract_t">Altena R, van Roon E, Folkeringa R, et al. Clinical challenges related to novel oral anticoagulants: drug-drug interactions and monitoring. Haematologica 2014; 99:e26.</a></li><li><a class="nounderline abstract_t">Siegal DM, Konkle BA. What is the effect of rivaroxaban on routine coagulation tests? Hematology Am Soc Hematol Educ Program 2014; 2014:334.</a></li><li><a class="nounderline abstract_t">Liakoni E, Rätz Bravo AE, Terracciano L, et al. Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban. JAMA Intern Med 2014; 174:1683.</a></li><li><a class="nounderline abstract_t">Caldeira D, Barra M, Santos AT, et al. Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. Heart 2014; 100:550.</a></li><li class="breakAll">http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf (Accessed on September 04, 2014).</li><li class="breakAll">https://www.fda.gov/news-events/press-announcements/fda-approves-first-generics-eliquis (Accessed on January 02, 2020).</li><li class="breakAll">http://packageinserts.bms.com/pi/pi_eliquis.pdf (Accessed on September 05, 2014).</li><li><a class="nounderline abstract_t">Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368:699.</a></li><li><a class="nounderline abstract_t">Holt A, Strange JE, Rasmussen PV, et al. Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients with Atrial Fibrillation on Apixaban, Rivaroxaban, or Dabigatran. Am J Med 2022; 135:595.</a></li><li class="breakAll">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202155s012lbl.pdf (Accessed on November 08, 2016).</li><li class="breakAll">http://www.pfizer.ca/sites/g/files/g10028126/f/201607/ELIQUIS_PM_184464_16June2016_E_marketed.pdf (Accessed on November 08, 2016).</li><li><a class="nounderline abstract_t">Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 2008; 6:820.</a></li><li><a class="nounderline abstract_t">Camm AJ, Bounameaux H. Edoxaban: a new oral direct factor xa inhibitor. Drugs 2011; 71:1503.</a></li><li><a class="nounderline abstract_t">Dentali F, Riva N, Crowther M, et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 2012; 126:2381.</a></li><li class="breakAll">http://www.daiichisankyo.com/news/detail/004033.html (Accessed on November 07, 2012).</li><li><a class="nounderline abstract_t">Hokusai-VTE Investigators, Büller HR, Décousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369:1406.</a></li><li><a class="nounderline abstract_t">Okumura K, Akao M, Yoshida T, et al. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. N Engl J Med 2020; 383:1735.</a></li><li class="breakAll">http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf (Accessed on January 09, 2015).</li><li class="breakAll">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206316s004lbl.pdf (Accessed on November 08, 2016).</li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208383s000lbl.pdf (Accessed on June 23, 2017).</li><li><a class="nounderline abstract_t">Cairns JA, Weitz JI. Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding. Am Heart J 2015; 169:1.</a></li><li><a class="nounderline abstract_t">Granger CB, Lopes RD, Hanna M, et al. Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Am Heart J 2015; 169:25.</a></li><li><a class="nounderline abstract_t">Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv 2018; 2:3257.</a></li><li class="breakAll">http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&amp;folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf (Accessed on April 30, 2015).</li><li class="breakAll">http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf (Accessed on June 02, 2015).</li><li class="breakAll">http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf (Accessed on April 30, 2015).</li><li class="breakAll">http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf (Accessed on April 30, 2015).</li><li class="breakAll">http://packageinserts.bms.com/pi/pi_eliquis.pdf (Accessed on April 30, 2015).</li></ol></div><div id="topicVersionRevision">Topic 1370 Version 164.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16148288" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Direct thrombin inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2374926" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The structure of a complex of recombinant hirudin and human alpha-thrombin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2369893" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Crystal structure of the thrombin-hirudin complex: a novel mode of serine protease inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10227240" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : New antithrombotic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10464282" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Thrombin interacts with thrombomodulin, protein C, and thrombin-activatable fibrinolysis inhibitor via specific and distinct domains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8202520" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Molecular mapping of the heparin-binding exosite of thrombin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2384594" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18096568" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : New oral anticoagulants in atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7855788" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8087958" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Direct thrombin inhibitors in cardiovascular medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19888525" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16161994" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20888031" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25119051" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Comment on: editorial by Husted et al. "Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel". (Thromb Haemost 2014; 111: 781-782).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25119344" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Response to Ansell et al. "Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel". (Thromb Haemost 2014; 112: 841).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24658395" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25880598" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22302737" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27786333" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30776320" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effectiveness and Safety of Off-Label Dose-Reduced Direct Oral Anticoagulants in Atrial Fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31307056" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33073581" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Direct Oral Anticoagulant Use in Chronic Kidney Disease and Dialysis Patients With Venous Thromboembolism: A Systematic Review of Thrombosis and Bleeding Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26121536" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : How to Monitor Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Practice Tool Endorsed by Thrombosis Canada, the Canadian Stroke Consortium, the Canadian Cardiovascular Pharmacists Network, and the Canadian Cardiovascular Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24996233" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25871670" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Site-level variation in and practices associated with dabigatran adherence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26356595" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23499350" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Thromboprophylaxis in the oldest old with atrial fibrillation: between Scylla and Charybdis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37139824" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : American Geriatrics Society 2023 updated AGS Beers Criteria®for potentially inappropriate medication use in older adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31764956" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Association of Anticoagulant Therapy With Risk of Fracture Among Patients With Atrial Fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32006423" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Fracture risks among patients with atrial fibrillation receiving different oral anticoagulants: a real-world nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28324091" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Association Between Dabigatran vs Warfarin and Risk of Osteoporotic Fractures Among Patients With Nonvalvular Atrial Fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28672314" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Osteoporotic Fractures Associated With Dabigatran vs Warfarin-Reply.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28672311" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Osteoporotic Fractures Associated With Dabigatran vs Warfarin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574264" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8149517" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8149517" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18449412" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Bivalirudin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2022012" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Combined administration of aspirin and a specific thrombin inhibitor in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2022012" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Combined administration of aspirin and a specific thrombin inhibitor in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10730687" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10730687" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11960487" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Structure-based design of novel potent nonpeptide thrombin inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11960487" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Structure-based design of novel potent nonpeptide thrombin inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11960487" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Structure-based design of novel potent nonpeptide thrombin inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20352166" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20214409" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18006647" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18006647" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22122184" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22122184" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22122184" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22122184" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34259389" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25523236" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Real-world variability in dabigatran levels in patients with atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24076487" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24814491" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Regarding the effect of dabigatran plasma concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24814492" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Reply: regarding the effect of dabigatran plasma concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25056265" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Dabigatran, bleeding, and the regulators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25756434" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Are new oral anticoagulant dosing recommendations optimal for all patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29754667" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29433148" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23232017" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22306274" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Interpretation of point-of-care INR results in patients treated with dabigatran.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22306274" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Interpretation of point-of-care INR results in patients treated with dabigatran.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22306274" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Interpretation of point-of-care INR results in patients treated with dabigatran.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23484796" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Dabigatran and postmarketing reports of bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23484796" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Dabigatran and postmarketing reports of bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23702623" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23855420" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Adherence to anticoagulant treatment with dabigatran in a real-world setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22444784" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19717844" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Dabigatran versus warfarin in patients with atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23103906" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29519351" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Non-Vitamin K Antagonist Oral Anticoagulants and Risk of Serious Liver Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17979700" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23995608" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34871048" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34633836" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Rivaroxaban Is Associated With Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants : A Nationwide Propensity Score-Weighted Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32150751" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Effectiveness and Safety of Apixaban Compared With Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice: A Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23216682" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26842561" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30580716" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Outcomes After Use of Standard- and Low-Dose Non-Vitamin K Oral Anticoagulants in Asian Patients With Atrial Fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28601546" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Influences of Obesity and Bariatric Surgery on the Clinical and Pharmacologic Profile of Rivaroxaban.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34820876" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI≥50 kg/m2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34904263" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Multi-center retrospective study evaluating the efficacy and safety of apixaban versus warfarin for treatment of venous thromboembolism in patients with severe obesity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35640233" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Direct oral Xa inhibitors for the treatment of venous thromboembolism after bariatric surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35640233" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Direct oral Xa inhibitors for the treatment of venous thromboembolism after bariatric surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25880707" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Of men and meals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22664783" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation–the J-ROCKET AF study–.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22813718" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23337693" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Confirmation of model-based dose selection for a Japanese phase III study of rivaroxaban in non-valvular atrial fibrillation patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31623498" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J-ROCKET AF Trials) in Asian Patients With Atrial Fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32981924" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : A Multicenter Prospective Observational Cohort Study to Investigate the Effectiveness and Safety of Rivaroxaban in Japanese Venous Thromboembolism Patients (The J'xactly Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32981924" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : A Multicenter Prospective Observational Cohort Study to Investigate the Effectiveness and Safety of Rivaroxaban in Japanese Venous Thromboembolism Patients (The J'xactly Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22931521" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21359645" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Drug and dietary interactions of warfarin and novel oral anticoagulants: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21245113" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24497568" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Clinical challenges related to novel oral anticoagulants: drug-drug interactions and monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25696875" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : What is the effect of rivaroxaban on routine coagulation tests?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25155865" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24476812" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24476812" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24476812" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24476812" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23216615" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Apixaban for extended treatment of venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34861201" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients with Atrial Fibrillation on Apixaban, Rivaroxaban, or Dabigatran.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34861201" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients with Atrial Fibrillation on Apixaban, Rivaroxaban, or Dabigatran.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34861201" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients with Atrial Fibrillation on Apixaban, Rivaroxaban, or Dabigatran.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18315548" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21861537" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Edoxaban: a new oral direct factor xa inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23071159" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23071159" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23991658" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32865374" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32865374" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32865374" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32865374" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25497240" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25497244" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30482765" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
